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ABSTRACT	  
High–throughput	  screening	  is	  a	  scientific	  method	  that	  can	  be	  used	  to	  identify	  small	  
compounds	   with	   activity	   against	   a	   number	   of	   bacteria	   and	   other	   organisms,	   as	   well	   as	  
diseases,	   such	   as	   cancer,	   in	   a	   cost	   efficient	   manner	   within	   reasonable	   time	   frames.	   The	  
absence	   of	   an	   effective	   HTS	   method	   for	   large-­‐scale	   compound	   screening	   in	   Chlamydia	  
hinders	   the	   identification	   of	   anti-­‐chlamydial	   compounds	   that	   could	   serve	   as	   novel	  
therapeutics,	   model	   molecules	   for	   the	   development	   of	   specific	   treatments,	   or	   molecular	  
probes	   to	   gain	   insight	   into	   the	   basic	   biology	   of	   the	   organism.	   The	   absence	   of	   a	   high-­‐
throughput	  screening	  method	  is	  highly	  influenced	  by	  the	  obligate,	  intracellular	  nature	  of	  the	  
organism,	   making	   enumeration	   of	   infection	   a	   time	   consuming	   and	   labor-­‐intensive	   task,	  
traditionally	  performed	  using	  an	   immunofluorescence	  assay.	  Recently	   in	  our	   laboratory,	  a	  
new	   method	   for	   enumerating	   chlamydial	   infection	   was	   developed	   using	   a	   cell	   viability	  
indicator,	   resazurin,	   to	   measure	   the	   reducing	   capability	   of	   the	   infected,	   eukaryotic	   host	  
cells.	  In	  this	  study,	  the	  resazurin-­‐based	  microplate	  assay	  was	  adapted	  to	  a	  high-­‐throughput	  
screening	   format	   and	   validated	   by	   screening	   the	   Prestwick	   Chemical	   library,	   containing	  
many	   known	   anti-­‐bacterial	   compounds,	   including	   anti-­‐chlamydial	   compounds.	   An	  
orthogonal	  assay	  was	  performed	  to	  further	  confirm	  the	  novel	  hits	  identified	  in	  the	  screen	  of	  
the	  Prestwick	  Chemical	  library	  and	  to	  begin	  to	  identify	  the	  mechanisms	  of	  inhibition	  exuded	  
on	   Chlamydia	   by	   those	   compounds.	   This	   high-­‐throughput	   screening	   method	   was	   further	  
adapted	   to	  automated	   liquid	  handling,	   including,	  plating	  and	   infecting	   the	  eukaryotic	  host	  
cells,	   and	   the	   assay	   quality	   and	   reproducibility	   were	   verified	   by	   the	   HTS	   Facility	   at	   The	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I. CHLAMYDIA	  INTRODUCTION	  
	  
A. HISTORY	  AND	  PUBLIC	  HEALTH	  IMPACT	  
The	   obligate,	   intracellular	   organism,	   Chlamydia	   trachomatis	   is	   a	   member	   of	   the	  
phylum	   Chlamydiae,	   which	   is	   composed	   of	   bacterial	   organisms	   that	   inhabit	   a	  
parasitophorous	  vacuole,	   termed	   inclusion,	   inside	  of	  a	  eukaryotic	  host	   (1).	  Chlamydia	  was	  
discovered	  over	  a	  century	  ago	  and	  called	  “Chlamydozoa”	  but	  was	  not	  classified	  as	  protozoa	  
or	  bacteria.	  At	  the	  time	  of	  discovery	  this	  organism	  was	  considered	  to	  be	  a	  virus	  and	  was	  not	  
accurately	   identified	   as	   a	   bacterium	   until	   the	   1960’s	   (2).	   It	   is	   now	   called	  
Chlamydia	  trachomatis	  and	  is	  the	  causative	  agent	  of	  trachoma,	  an	  ocular	  infection	  that	  can	  
lead	   to	  blindness	   (3).	  The	  earliest	   reliable	  descriptions	  of	   trachoma	  date	  back	   to	  1553	  BC	  
but	  the	  link	  between	  Chlamydia	  and	  humans	  likely	  predates	  civilization	  (4).	  Despite	  the	  long	  
history	  of	  trachoma	  infections,	  it	  is	  still	  a	  major	  health	  concern	  and	  was	  listed	  as	  one	  of	  the	  
top	  seven	  neglected	  diseases	  in	  the	  21st	  century	  (5).	  
Chlamydia	  infections	  in	  humans	  are	  predominantly	  caused	  by	  two	  different	  species,	  
Chlamydia	  pneumoniae	  and	  Chlamydia	  trachomatis,	  and	  both	  have	   a	   significant	   and	  global	  
health	   impact.	  C.	  pneumoniae	  is	  most	  commonly	  a	  respiratory	  pathogen	  responsible	   for	  6-­‐
22%	  of	  community	  acquired	  pneumonias	  and	  serological	  studies	  indicate	  that	  almost	  every	  
individual	   has	   been	   exposed	   to	   C.	   pneumoniae	   	   at	   some	   point	   in	   life	   (6).	   There	   is	   also	  
evidence	  of	  this	  bacteria’s	  role	  in	  atherosclerosis	  and	  coronary	  artery	  disease,	  which	  is	  the	  
leading	  cause	  of	  death	  for	  both	  men	  and	  women	  in	  the	  developed	  world	  (7-­‐9).	  In	  addition	  to	  
causing	   ocular	   infections	   that	   can	   lead	   to	   blindness,	  C.	  trachomatis	  can	   also	   cause	   genital	  
infections.	  This	  species	  of	  Chlamydia	  is	  the	  leading	  cause	  of	  infectious	  blindness	  worldwide	  
and	   the	   most	   commonly	   reported	   sexually	   transmitted	   infection	   in	   the	   United	   States,	  
comprising	   the	   largest	   proportion	   of	   sexually	   transmitted	   diseases	   reported	   to	   the	   CDC	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since	  1994	  (10).	  Most	  people	  with	  C.	  trachomatis	  genital	  infections	  are	  asymptomatic	  and	  if	  
left	   untreated	   these	   infections	   can	   lead	   to	   chronic	   inflammation	   and	   severe	  health	   issues,	  
particularly	   for	   women,	   such	   as	   pelvic	   inflammatory	   disease,	   life-­‐threatening	   ectopic	  
pregnancy	  and	  infertility	  (11,	  12)	  
Chlamydia	  trachomatis	   can	   be	   further	   broken	   down	   into	   serotypes	   based	   on	   the	  
composition	  of	   their	  highly	   immunogenic,	  major	  outer	  membrane	  protein	   (MOMP),	  which	  
contains	   epitopes	   that	   are	   genus,	   species,	   subspecies	   and	   serotype	   specific	   (13).	   	   The	  
original	   classification	   identified	   fifteen	   MOMP	   serovars	   but	   subsequent	   studies	   have	  
expanded	  the	  list	  of	  chlamydial	  strains	  to	  over	  twenty	  genovars,	  serovars	  and	  serovariants	  
(14,	  15)	  Trachoma	  is	  caused	  by	  serotypes	  A,	  B,	  Ba	  and	  C,	  which	  infect	  the	  conjunctiva	  of	  the	  
eye,	  and	  repeat	   infections	  can	   lead	   to	  scarring	  and	  visual	   impairment	  (16).	   It	   is	  estimated	  
that	   approximately	   40	   million	   people	   have	   active	   trachoma,	   1.8	   million	   have	   visual	  
impairment	  from	  infection	  and	  an	  additional	  1.3	  million	  people	  are	  blind	  from	  the	  disease	  
worldwide	  (17).	  Serotypes	  D	  through	  K	  are	  responsible	  for	  oculogenital	  infections	  that	  are	  
sexually	   transmitted	   (13).	   The	   World	   Health	   Organization	   determined	   that	   there	   are	  
approximately	   90	  million	   cases	   of	  Chlamydia	  trachomatis	   infections	   reported	   annually.	  Of	  
those	  cases,	  it	  is	  estimated	  that	  four	  million	  are	  reported	  in	  the	  United	  States	  and	  5.5	  million	  
cases	  of	  infection	  are	  reported	  in	  Europe	  each	  year	  (18).	  However,	  these	  numbers	  may	  not	  
accurately	  represent	  the	  annual	  number	  of	  infections	  because	  up	  to	  50%	  of	  men	  and	  up	  to	  
80%	   of	   women	   remain	   asymptomatic,	  making	   diagnosis	   and	   treatment	   difficult	   (19,	   20).	  
Serotypes	  D	   through	  K	   are	  not	   limited	   to	   genital	   infections	   and	   can	   also	   cause	   the	   ocular	  
diseases	  opthalmia	  neonatorum	  and	  paratrachoma	  (21).	  In	  addition	  to	  serotypes	  D	  through	  
K	   	   that	  are	   capable	  of	   causing	  genital	   infections,	   there	   is	   the	   lymphogranuloma	  venereum	  
(LGV)	   pathovar	   composed	   of	   serotypes	   L1,	   L2	   and	   L3.	   The	   distinguishing	   difference	  
between	  these	  serotypes	  is	  D	  through	  K	  are	  non-­‐invasive,	  but	  L1	  through	  L3	  are	  capable	  of	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infecting	  monocytes	   and	   disseminating	   infection	   to	   the	   local	   draining	   lymph	   nodes	   (22).	  
LGV	   can	   have	   genital	   and	   extragenital	   manifestations	   and	   is	   endemic	   in	   East	   and	   West	  
Africa,	  Southeast	  Asia,	  India,	  the	  Caribbean	  basin	  and	  South	  America	  (23).	  	  
In	  addition	  to	  their	  human	  hosts,	  members	  of	  Chlamydiae	  infect	  a	  variety	  of	  mostly	  
mammalian	  animal	  hosts.	  Chlamydia	  felis	  and	  Chlamydia	  caviae	  both	  cause	  conjunctivitis	  in	  
cats	  and	  in	  guinea	  pigs,	  respectively	  (24).	  Chlamydia	  muridarum	  infects	  mice	  and	  is	  a	  strain	  
closely	   related	   to	  C.	  trachomatis.	   It	   is	  of	  medical	   importance	  because	  mice	  can	  be	   infected	  
and	   studied	   as	   an	   appropriate	   animal	  model	   to	   test	   treatment	   options	   and	   obtain	   insight	  
into	   the	   immunological	   pathology	   of	   Chlamydia	  trachomatis	   (25).	   There	   are	   a	   variety	  
chlamydial	   species	   that	   infect	  pig	  herds	  at	   a	  high	  prevalence,	   including	  Chlamydia	  suis,	   an	  
intestinal	  pathogen	  of	  swine	  (26).	  Chlamydia	  psittaci	  is	  arguably	  the	  most	  important	  species	  
of	  Chlamydiae	  animal	  pathogens	  because	  along	  with	  its	  common	  host,	  parrots	  and	  poultry,	  it	  
is	   also	  a	  human	  zoonotic	  pathogen,	   causing	  potentially	  deadly	   respiratory	  psittacosis	   (27,	  
28).	   	  C.	   psittaci	   is	   particularly	   dangerous	   because	   it	   is	   highly	   infective	   and	   thought	   to	   be	  
transmitted	  through	  aerosols,	  making	  it	  a	  candidate	  for	  biosubstance	  regulation	  (29).	  Given	  
the	  global	  health	  impact,	  diversity	  of	  hosts	  and	  diseases	  caused	  by	  Chlamydiae	  species,	  it	  is	  
evident	   that	   these	   bacteria	   are	   of	   medical	   importance	   but	   many	   key	   factors	   about	   these	  
organisms’	  basic	  biology	  and	  their	  pathogenic	  mechanisms	  are	  fully	  understood.	  	  
	  
B. TREATMENT	  AND	  VACCINE	  
In	  addition	  to	  the	  global	  impact	  Chlamydia	  has	  and	  the	  high	  incidences	  of	  infection	  
annually,	   repeat	   chlamydial	   infections	   are	   a	   common	   occurrence.	   One	   report	   stated	   that	  
people	  under	  25	  years	  of	  age	  had	  a	  reinfection	  rate	  as	  high	  as	  24%,	  which	  was	  the	  highest	  
observed	   among	   all	   of	   the	   populations	   studied	   (30).	   The	   rate	   of	   reinfection	   is	   highly	  
influenced	   by	   untreated	   partners,	   whom	   may	   not	   know	   they	   are	   infected	   due	   to	   the	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common	   asymptomatic	   nature	   of	  Chlamydia	   infections.	   It	   is	   the	   silent	   nature	   of	   infection	  
that	  causes	  complications	  in	  diagnosis	  and	  treatment	  of	  Chlamydia.	  	  
The	   two	  most	   commonly	   prescribed	   antibiotics	   used	   for	   treatment	   of	   chlamydial	  
infections	  are	  doxycycline	  and	  azithromycin.	  Doxycycline	  is	  a	  typical	  tetracycline	  antibiotic	  
and	  a	  known	  bacterial	  protein	   synthesis	   inhibitor	   (31).	   	  Azithromycin	   is	   a	  member	  of	   the	  
macrolide	   antibiotic	   family	   and	   is	   structurally	   similar	   to	   erythromycin	   but	   has	   increased	  
activity	  against	  Gram-­‐negative	  bacteria,	   such	  as	  Chlamydia	  trachomatis	  (32).	  Azithromycin	  
is	  given	  in	  a	  high,	  single	  dose	  and	  doxycycline	  is	  prescribed	  in	  a	  lower	  dose	  twice	  daily	  for	  
seven	  days	  (33).	  Despite	  their	  differences	  in	  treatment	  regiments,	  both	  of	  these	  antibiotics	  
are	   currently	   recommended	   as	   equal	   treatment	   choices	   for	   uncomplicated	   Chlamydia	  
infections	  (34,	  35).	  With	  these	  two	  antibiotics,	  most	  Chlamydia	  infections	  can	  be	  treated	  but	  
tetracycline	  resistance	  has	  been	  observed	  in	  Chlamydia	  suis,	  an	  intestinal	  pathogen	  of	  pigs,	  
indicating	   that	   resistance	   can	   be	   obtained	   under	   environmental	   pressures	   and	   treatment	  
failures	  do	  occur	  (36).	  Treatment	  failures	  have	  been	  recorded	  for	  both	  antibiotics	  that	  are	  
prescribed	   but	   higher	   incidences	   of	   failures,	   as	   high	   as	   8%,	   have	   been	   reported	   for	  
azithromycin	   if	   the	   treatment	   regiment	   is	   strictly	   followed	   for	   doxycycline	   (37).	   A	   third	  
antibiotic,	   amoxicillin,	   which	   is	   a	   beta-­‐lactam	   antibiotic	   and	   a	   member	   of	   the	   penicillin	  
family	  of	  antibiotics,	  may	  be	  prescribed	  for	  treatment	  of	  Chlamydia	  if	  a	  woman	  is	  pregnant	  
and	   allergic	   to	   macrolide	   antibiotics	   to	   avoid	   the	   dangerous	   side	   effects	   of	   doxycycline	  
during	   pregnancy	   and	   to	   prevent	   transmission	   of	   Chlamydia	   to	   the	   child	   when	   it	   passes	  
through	   the	  birth	   canal	   (38,	   39).	   Fluoroquinolone	   antibiotics,	   such	   as	   ofloxacin,	   have	   also	  
been	  reported	  to	  be	  effective	  against	  Chlamydia	  infections	  but	  are	  not	  recommended	  as	  the	  
first	   treatment	   options	   due	   to	   the	   adverse	   effects	   on	   the	  musculoskeletal	   system	   and	   the	  
CNS	  that	  this	  class	  of	  antibiotics	  can	  cause	  (40).	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Given	   the	   high	   incidence	   of	   infection,	   reinfection	   and	   the	   asymptomatic	   nature	   of	  
Chlamydia,	  prevention	  of	  infection	  would	  be	  preferred.	  Prevention	  could	  occur	  by	  two	  main	  
methods	   for	   sexually	   active	   individuals;	   a	   barrier	   from	   the	   organism	   to	   prevent	  
transmission	  or	  a	  vaccine	  to	  aid	  in	  the	  elimination	  of	  the	  organism	  before	  infection	  occurs.	  
Currently,	   condoms	   serve	   as	   the	   primary	   method	   for	   prevention	   of	   infection	   but	   in	   the	  
absence	   of	   regular	   condom	   use,	   there	   is	   not	   a	   female-­‐controlled	   preventative	   method	  
currently	  available	  on	  the	  market,	  such	  as	  vaginal	  microbicide.	  In	  addition	  to	  the	  absence	  of	  
an	   effective	   microbicide	   and	   despite	   numerous	   efforts,	   a	   vaccine	   has	   also	   not	   been	  
successfully	   developed	   for	   use	   in	   humans.	   Advancements	   in	   the	   understanding	   of	   the	  
immunobiology	   of	   C.	  muridarum	   has	   allowed	   for	   the	   creation	   of	   a	   common	   model	   of	  
immunity	  with	  C.	  trachomatis	  but	  further	  research	  is	  needed	  to	  develop	  a	  safe	  and	  effective	  
vaccine	  candidate	  (41,	  42).	  	  
	  
C. DEVELOPMENTAL	  CYCLE	  
The	   Gram-­‐negative,	   eubacteria	   Chlamydia	   is	   characterized	   by	   its	   unique,	   biphasic	  
developmental	   cycle	   in	   which	   it	   exists	   in	   two	   distinct,	   morphological	   forms;	   the	   small	  
(0.3	  μm),	   infectious,	   metabolically	   inert,	   electron-­‐dense,	   elementary	   body	   and	   the	   larger	  
(1	  μm),	   non-­‐infectious,	   metabolically	   active,	   reticulate	   body	   (43,	   44).	   Despite	   the	   wide	  
variety	  of	  hosts	  and	  tissues	  that	  each	  species	  infects,	  all	  chlamydial	  species	  have	  a	  parasitic	  
nature	  and	  require	   their	  eukaryotic	  hosts	   for	  growth	  and	  replication.	  The	  existence	  of	   the	  
biphasic	  developmental	  cycle	  is	  also	  conserved	  between	  species	  but	  the	  timing	  of	  the	  major	  
events	  of	  the	  developmental	  cycle	  vary	  between	  species	  and	  serotypes	  (45).	  	  
Chlamydia	  infection	  is	  initiated	  by	  the	  attachment	  of	  an	  elementary	  body	  (EB)	  to	  the	  
cell	   membrane	   of	   a	   terminally	   differentiated,	   non-­‐phagocytic,	   epithelial	   cell	   (Fig.	   1).	  
Attachment	  to	  the	  host	  cell	  occurs	  in	  two	  stages;	  the	  first	  stage	  is	  reversible,	  electrostatic	  	  







Figure	   1:	   Developmental	   Cycle	   of	   Chlamydia	  trachomatis.	   Throughout	   the	  
developmental	  cycle,	  Chlamydia	  exists	  in	  two	  forms;	  the	  small,	  infectious,	  elementary	  body	  
(EB)	  and	  the	  larger,	  non-­‐infectious,	  reticulate	  body	  (RB).	  At	  0	  hours	  post	  infection	  (hpi)	  the	  
EB	   attaches	   and	   induces	   its	   uptake	   into	   a	   terminally	   differentiated,	   non-­‐phagocytic,	  
epithelial	   cell.	  After	  approximately	  2	  hpi,	   the	  EB	  has	  entered	   the	  host	  cell	  and	   formed	   the	  
parasitophorous	   vacuole,	   termed	   inclusion.	   At	   approximately	   6-­‐8	   hpi	   the	   EB	  will	   convert	  
into	   the	   metabolically	   active	   RB	   and	   begin	   cell	   division	   by	   binary	   fission,	   which	   will	  
continue	  throughout	  the	  remainder	  of	  the	  developmental	  cycle.	  At	  approximately	  18-­‐24	  hpi	  
the	  RBs	  will	  begin	  to	  asynchronously	  differentiate	  back	  into	  newly	  formed,	   infectious	  EBs.	  
The	  initial	  cycle	  of	  infection	  is	  completed	  after	  48-­‐72	  hpi	  when	  the	  organisms	  are	  released	  
into	  the	  surrounding	  environment	  by	  host	  cell	  lysis	  or	  the	  process	  of	  extrusion.	  Hours	  post	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interactions	  and	  the	  second	  is	  irreversible	  attachment	  (43).	  The	  EB	  induces	  its	  uptake	  into	  
the	   host	   cell	   by	   means	   of	   its	   type	   III	   secretion	   system	   (TTSS)	   and	   promptly	   forms	   the	  
inclusion	   that	   is	  modified	   to	   prevent	   fusion	  with	   the	   host	   cell	   lysosomes	   (46).	   Inside	   the	  
inclusion,	   the	  EB	  converts	   into	  a	  reticulate	  body	  (RB)	  and	  after	  approximately	  six	   to	  eight	  
hours	  it	  begins	  dividing	  by	  binary	  fission	  resulting	  in	  two	  daughter	  cells	  of	  about	  equal	  size	  
(47,	   48).	   At	   approximately	   18	   to	   24	   hours	   post	   infection,	   RBs	   begin	   asynchronously	  
differentiating	   back	   into	   infectious	   EBs	   that	   gather	  mainly	   in	   the	   center	   of	   the	   inclusion,	  
allowing	  the	  RBs	  to	  continue	  to	  obtain	  nutrients	  from	  the	  host	  by	  localizing	  at	  the	  inclusion	  
membrane	  (49,	  50).	  The	  initial	  cycle	  of	  infection	  is	  completed	  after	  48	  to	  72	  hours	  when	  the	  
newly	   formed	  EBs,	   capable	  of	   initiating	   a	   second	   round	  of	   infection,	   are	   released	   into	   the	  
surrounding	   environment	   by	   host	   cell	   lysis	   or	   the	   process	   of	   extrusion	   (51).	   Despite	   the	  
characterization	  of	  the	  biphasic	  developmental	  cycle	  of	  Chlamydia,	   the	  signals	  that	  control	  
the	  cycle	  and	  the	  mechanisms	  that	  the	  organism	  uses	  to	  modulate	  the	  host	  cell’s	  function	  to	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II. ADAPTATION	  AND	  VERIFICATION	  OF	  A	  HTS	  METHOD	  FOR	  CHLAMYDIA	  	  
	  
A. INTRODUCTION	  	  
	  
Chemical	  Biology	  and	  High-­‐throughput	  Screening:	  
Chlamydia’s	  basic	  biology	  and	  pathogenic	  mechanisms	  are	  poorly	  understood	  even	  
given	   this	   organism’s	   broad	   and	   relevant	   public	   health	   impact.	   This	   deficiency	   in	  
understanding	   is	   due,	   in	  part,	   to	   challenges	   since	   it	   is	   an	  obligate,	   intracellular	  bacterium	  
with	   a	   biphasic	   developmental	   cycle,	   containing	   numerous	   essential	   growth	   stages	   and	   a	  
deficiency	  in	  basic	  genetic	  manipulation	  capabilities	  within	  the	  organism.	  Until	  Wang	  et	  al.	  
was	  published	  in	  2011,	  a	  method	  describing	  the	  transformation	  of	  stable	  DNA	  in	  the	  form	  of	  
a	   shuttle	  vector	   into	  Chlamydia	  had	  not	  been	  established	   (52).	  Since	   the	   introduction	  of	  a	  
transformation	  system,	  several	  advances	  have	  been	  made	  in	  the	  field,	  such	  as	  an	  inducible	  
gene	   expression	   system	   under	   the	   control	   of	   the	   Tet	   operator	   and	   the	   identification	   of	   a	  
method	  allowing	  for	  transformation	  of	  Chlamydia	  growing	  within	  the	  host	  cell	  inclusion,	  but	  
it	  is	  still	  not	  possible	  to	  successfully	  knockout	  genes	  in	  this	  organism	  (53-­‐55).	  	  
An	   alternative	   method	   to	   study	   Chlamydia	   and	   gain	   information	   about	   its	   basic	  
biology	   is	   to	   use	   chemical	   biology,	   which	   is	   a	   scientific	   discipline	   that	   uses	   chemical	  
techniques	   to	   study	  biological	   functions	   and	  processes.	   If	   a	   small	   compound	  with	   activity	  
against	   an	   organism	   is	   identified,	   it	   can	   be	   utilized	   as	   a	   molecular	   probe	   to	   tease	   out	  
information	  about	  the	  basic	  biology	  of	  what	  is	  being	  studied.	  The	  chemical	  biology	  approach	  
utilizing	  a	  molecular	  probe	  has	  been	  widely	  used	  to	  gain	  insight	  into	  physiological	  systems,	  
such	  as	  sodium	  transport	  into	  cells	  and	  tissues,	  and	  molecular	  probes	  can	  be	  conjugated	  to	  
fluorescent	  molecules	  enabling	  localization	  studies	  (56,	  57).	  By	  identifying	  small	  molecules	  
or	  compounds	   that	   inhibit	  or	   stall	   the	  developmental	   cycle	  of	  Chlamydia	   and	   isolating	   the	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targets	  of	  those	  compounds,	  we	  can	  gain	  insight	  into	  the	  basic	  biology	  of	  the	  organism	  and	  
its	   virulence	   mechanisms.	   In	   addition	   to	   the	   paucity	   of	   genetic	   manipulation	   in	  
C.	  trachomatis,	  there	  are	  currently	  only	  two	  antibiotics	  commonly	  prescribed	  for	  treatment	  
of	   Chlamydia	  trachomatis	   infections;	   azithromycin	   and	   doxycycline	   (19).	   Most	   Chlamydia	  
infections	   can	   be	   treated	  with	   doxycycline	   or	   azithromycin,	   but	   resistance	   to	   tetracycline	  
antibiotics	  have	  been	  observed	  in	  other	  species	  of	  Chlamydia	  (36).	  Not	  only	  could	  we	  gain	  
information	  from	  molecular	  probes	  about	  Chlamydia	  by	  using	  a	  chemical	  biology	  approach,	  
but	   the	   identified	   compounds	   could	   also	   serve	   as	  model	  molecules	   to	   design	  specific	   and	  
novel	  therapeutics	  to	  treat	  infections.	  	  
	   	  One	  method	  to	  identify	  compounds	  to	  be	  used	  as	  molecular	  probes	  or	  model	  
molecules	  is	  by	  high-­‐throughput	  screening	  of	  small,	  compounds	  libraries.	  High-­‐throughput	  
screening	  (HTS)	  is	  a	  scientific	  method	  that	  is	  commonly	  used	  to	  discover	  new	  drug	  
treatments	  in	  an	  economically	  friendly	  and	  in	  a	  reasonable	  time	  frame.	  There	  have	  been	  
several	  different	  methods	  that	  have	  been	  successfully	  adapted	  to	  HTS	  and	  can	  now	  be	  used	  
to	  identify	  compounds	  for	  potential	  treatment	  of	  a	  wide	  variety	  of	  bacteria,	  parasites,	  fungi,	  
and	  cancer	  (58-­‐62).	  However,	  there	  is	  currently	  not	  a	  high-­‐throughput	  screening	  method	  to	  
identify	  compounds	  with	  activity	  against	  Chlamydia.	  This	  void	  is	  potentially	  due	  to	  the	  
obligate,	  intracellular	  nature	  of	  the	  organism	  and	  the	  inability	  to	  culture	  it	  outside	  of	  a	  
eukaryotic	  host	  cell,	  making	  enumeration	  of	  infection	  a	  labor-­‐intensive	  task.	  The	  level	  of	  
infection	  following	  treatment	  was	  traditionally	  determined	  by	  counting	  inclusions	  that	  are	  
fixed,	  stained	  and	  imaged	  using	  an	  immunofluorescence	  assay	  (IFA).	  Even	  with	  
advancements,	  such	  as	  image-­‐based	  automated	  chlamydial	  identification	  and	  enumeration,	  
iBAChIE,	  allowing	  for	  the	  automated	  enumeration	  of	  inclusions	  using	  widely	  available	  
software,	  IFA	  is	  still	  not	  a	  method	  suited	  for	  large	  scale	  HTS	  of	  small	  compound	  libraries	  
(63).	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   Resazurin-­‐based	  Microplate	  Assay:	  
A	  new,	  facile	  method	  for	  enumeration	  of	  Chlamydia	  infection,	  a	  resazurin-­‐based	  
microplate	  assay,	  was	  recently	  developed	  in	  our	  laboratory	  in	  a	  96-­‐well	  format.	  This	  
method	  drastically	  reduces	  the	  amount	  of	  time	  required	  for	  analysis	  and	  determination	  of	  
the	  level	  of	  infection	  of	  a	  sample	  and	  during	  validation,	  the	  results	  of	  this	  assay	  strongly	  
correlated	  with	  the	  results	  of	  inclusion	  enumeration	  by	  an	  immunofluorescence	  assay	  (IFA)	  
(64).	  The	  assay	  utilizes	  the	  cell	  viability	  indicator	  known	  commercially	  as	  alamarBlue,	  and	  
commonly	  as	  resazurin,	  as	  a	  colorimetric	  indicator	  of	  living	  cells.	  During	  the	  experiment,	  
resazurin,	  a	  blue,	  non-­‐fluorescent	  compound,	  is	  added	  to	  the	  infected	  and	  control	  host	  cells	  
at	  the	  end	  of	  the	  first	  cycle	  of	  infection,	  which	  should	  correlate	  with	  host	  cell	  lysis	  of	  
infected	  cells	  (Fig.	  2).	  If	  the	  cells	  are	  viable,	  the	  resazurin	  is	  converted	  into	  the	  red,	  
fluorescent,	  reduced	  form	  called	  resorufin	  by	  products	  of	  host	  cell	  metabolism.	  Since	  the	  
resazurin	  and	  resorufin	  absorb	  at	  different	  wavelengths	  and	  given	  that	  resazurin	  is	  non-­‐
fluorescent	  and	  resorufin	  is	  highly	  fluorescent,	  measuring	  the	  absorbance	  or	  the	  
fluorescence	  of	  each	  well	  allows	  for	  the	  calculation	  of	  the	  reducing	  capability	  of	  the	  cells.	  
The	  reducing	  capability	  of	  the	  host	  cells	  corresponds	  to	  cell	  viability,	  which	  inversely	  
correlates	  to	  the	  initial	  level	  of	  infection.	  	  
Resazurin	  is	  a	  colorimetric,	  cell	  viability	  indicator	  that	  has	  been	  used	  in	  several	  
successfully	  adapted	  high-­‐throughput	  screening	  methods	  of	  compounds	  against	  Aspergillus,	  
trypanosomes,	  Staphylococcus,	  and	  Mycobacterium	  (65-­‐68).	  Given	  the	  effectiveness	  of	  the	  
resazurin-­‐based	  microplate	  assay	  developed	  for	  enumeration	  of	  Chlamydia	  in	  96-­‐well	  
format,	  the	  method	  seemed	  well	  suited	  for	  adaptation	  to	  a	  smaller	  format	  more	  commonly	  
used	  in	  high-­‐throughput	  screening.	  In	  addition	  to	  a	  drastic	  reduction	  in	  analysis	  time,	  this	  
method	  also	  significantly	  reduces	  the	  number	  of	  liquid	  handling	  steps	  required	  to	  perform	  
the	  assay,	  making	  it	  more	  suitable	  to	  HTS	  compared	  to	  IFA.	  Once	  the	  assay	  is	  successfully	  	  







Figure	  2:	  384-­‐well	  Screening	  Method	  Schematic.	  On	  the	  first	  day,	  L929	  cells	  that	  have	  
been	  routinely	  cultured	  are	  seeded	  into	  a	  clear,	  384-­‐well,	  tissue	  culture	  plate.	  On	  the	  second	  
day,	  compounds	  to	  be	  screened	  are	  set	  out	  at	  RT	  for	  one	  hour	  before	  EBs	  are	  diluted	  to	  cell	  
culture	  medium	  and	  added	  to	  each	  of	  the	  wells	  of	  the	  compound	  plate.	  The	  medium	  is	  
aspirated	  off	  of	  the	  L929	  cells	  seeded	  the	  previous	  day	  and	  medium	  containing	  EBs	  and	  the	  
compounds	  to	  be	  tested	  are	  transferred	  from	  the	  compound	  plate	  to	  the	  designated	  wells	  
containing	  L929	  cells.	  Following	  a	  72	  hour	  incubation	  period,	  resazurin,	  known	  
commercially	  as	  alamarBlue,	  is	  added	  to	  the	  wells	  and	  allowed	  to	  incubate	  for	  an	  additional	  
8	  hours	  before	  the	  absorbance	  at	  570	  nm	  and	  600	  nm	  is	  read	  using	  a	  spectrophotometer.	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adapted	   to	   high-­‐throughput	   screening,	   it	   can	   be	   used	   to	   screen	   large	   libraries	   of	   small	  
compounds	  with	  drug	  or	  predicted	  drug	  activity	  and	  would	  fill	  a	  niche	  in	  the	  Chlamydia	  field	  
by	  allowing	  for	  a	  high-­‐throughput	  screening	  method	  capable	  of	  identifying	  novel	  therapies,	  
molecular	  probes	  or	  model	  molecules	  with	  activity	  against	  this	  organism.	  	  
	  
Statistical	  Evaluation	  of	  High-­‐throughput	  Screens:	  
Throughout	  the	  development	  and	  optimization	  of	  a	  high-­‐throughput	  screening	  
method,	  the	  functionality	  and	  effectiveness	  of	  the	  screen	  must	  be	  measured	  to	  ensure	  the	  
method	  is	  well	  suited	  for	  high-­‐throughput	  screening.	  The	  statistical	  parameters	  commonly	  
used	  to	  evaluate	  HTS	  assays	  throughout	  optimization	  and	  screening	  are	  Z’	  factor	  and	  Z	  
factor,	  which	  were	  originally	  described	  by	  Zhang	  et	  al.	  (69).	  Z	  factor	  is	  calculated	  using	  the	  
following	  formula;	  !   =   1  – (!!!!  !!!  )
|!!!  !!|
,	  where	  !!	  is	  the	  standard	  deviation	  of	  the	  samples,	  !!  	  
is	  the	  standard	  deviation	  of	  the	  respective	  control	  and	  !!	  and	  !! 	  are	  the	  means	  of	  the	  
sample	  data	  and	  the	  control	  data,	  respectively.	  The	  closer	  the	  resulting	  factor	  is	  to	  one,	  the	  
more	  ideal	  the	  assay	  is	  for	  HTS	  and	  the	  more	  reliable	  the	  data	  will	  be.	  	  Any	  factor	  value	  over	  
0.5	  is	  considered	  to	  be	  an	  excellent	  assay.	  Z’	  factor	  is	  calculated	  in	  a	  similar	  way	  as	  Z	  factor	  
but	  instead	  of	  evaluating	  sample	  and	  respective	  control	  data,	  Z’	  factor	  is	  calculated	  using	  the	  
positive	  and	  negative	  controls.	  Z’	  factor	  is	  primarily	  calculated	  to	  evaluate	  the	  assay	  as	  it	  is	  
being	  optimized	  and	  Z	  factor	  is	  calculated	  to	  assess	  the	  accuracy	  and	  quality	  of	  data	  
obtained	  during	  a	  screen	  of	  compounds.	  In	  any	  given	  situation,	  Z	  factor	  is	  less	  than	  or	  equal	  
to	  Z’	  factor	  and	  both	  are	  very	  susceptible	  to	  variation	  in	  the	  data	  and	  require	  a	  broad	  
separation	  band	  between	  the	  controls	  and	  samples	  to	  obtain	  an	  acceptable	  value.	  Therefore,	  
an	  excellent	  assay	  that	  is	  amendable	  for	  adaptation	  to	  HTS	  and	  will	  generate	  reliable	  data	  
needs	  to	  have	  a	  large	  dynamic	  range	  and	  small	  data	  variation,	  resulting	  in	  high	  Z’	  and	  Z	  
factors.	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In	   this	   study,	   the	   resazurin-­‐based	   microplate	   assay	   used	   for	   enumeration	   of	  
Chlamydia	  infection	  was	  successfully	  adapted	  to	  a	  smaller,	  384-­‐well	  format	  and	  the	  method	  
was	   verified	   by	   screening	   the	   diverse	   small-­‐compounds	   contained	   in	   the	   Prestwick	  
Chemical	   Library,	   including	   many	   known	   antibiotics.	   Following	   the	   initial,	   small-­‐scale	  
screen,	   an	   orthogonal,	   immunofluorescence	   assay,	   was	   performed	   using	   the	   top	   non-­‐
antibacterial	  compounds	  identified	  in	  the	  screen	  of	  the	  small,	  chemical	   library.	  Finally,	  the	  
method	  was	  further	  validated	  by	  adaptation	  to	  automated	  liquid	  handling	  and	  confirmation	  
of	   the	   reproducibility	  of	   the	  assay	  was	   completed	  by	   the	  HTS	   facility	   at	  The	  University	  of	  
Kansas.	  	  
	  
B. MATERIALS	  AND	  METHODS	  
	  
Cell	  Culture:	  
	  Murine,	  L929,	   fibroblast	  cells	  (ATCC	  CCL-­‐1)	  were	  routinely	  cultured	  in	  RPMI	  1640	  
medium	  (Cellgro	  by	  Mediatech;	  Manassas,	  VA	  20109)	  with	  phenol	  red,	  supplemented	  with	  
0.3	  mg/mL	  L-­‐glutamine,	  5%	  (vol/vol)	  fetal	  bovine	  serum	  (FBS)	  and	  10	  μg/mL	  gentamycin	  
at	  37°C,	  5%	  CO2.	  	  
	  
EB	  Preparation:	  	  
L929	  cells	  were	  grown	  in	  RPMI	  with	  phenol	  red,	  supplemented	  with	  0.3	  mg/mL	  L-­‐
glutamine,	  5%	  (vol/vol)	  fetal	  bovine	  serum	  (FBS)	  and	  10	  μg/mL	  gentamycin	  and	  incubated	  
at	  37°C,	  5%	  CO2	   in	  a	   spinner	   flask	  on	  a	  magnetic	  plate	   that	  generated	  slight,	  but	  constant	  
agitation.	   Once	   cells	   reached	   8	   x	   105	   cells/mL,	   previously	   isolated	   C.	  trachomatis	  
lymphogranuloma	   venereum	   (LGV)	   serovar	   L2/434/Bu	   seed	   was	   diluted	   into	   Hank’s	  
Balanced	  Salt	  Solution	  with	  Calcium	  and	  Magnesium	  (HBSS;	  Mediatech,	  Inc.,	  Manassas,	  VA)	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and	  was	  added	   to	   the	   spinner	   flask	  with	  a	   final	   concentration	  of	  1	  μg/mL	  cyclohexamide.	  
Approximately	  6	  hpi,	  a	  sample	  was	  removed	  from	  the	  spinner	   flask	  and	  seeded	   into	  an	  8-­‐
well	  Ibidi	  slide.	  At	  24	  hpi	  the	  approximate	  level	  of	  infection	  was	  determined	  and	  had	  to	  be	  
sufficient	   prior	   to	   purification	   of	   the	   EBs.	   At	   approximately	   48	   hpi	   and	   after	   continued	  
incubation	   at	   37°C,	   5%	   CO2	   on	   a	   magnetic	   plate,	   elementary	   bodies	   (EBs)	   were	   purified	  
from	   infected	   cells	  using	  a	  30%	  Renografin	  density	   gradient	   as	  previously	  described	   (70)	  
and	  stored	  in	  sucrose	  phosphate	  glutamate	  (SPG)	  buffer	  at	  -­‐80°C	  until	  needed.	  All	  of	  the	  EB	  
preparations	  were	  combined	  and	  aliquoted	  in	  small	  volumes	  allowing	  for	  a	  new	  aliquot	  to	  
be	   thawed	   for	   each	   experiment	   with	   approximately	   the	   same	   level	   of	   infectivity.	   The	  




L929	   cells	   were	   seeded	   1.0	  x	  105	  cells/mL;	  50	  μl/well	   in	   a	   clear,	   384-­‐well	   tissue	  
culture	   plate	   (Thermo	   Scientific,	   Nunc	   164688)	   and	   incubated	   flat	   at	   RT	   to	   reduce	   edge	  
effect.	   After	   1	   hour,	   cells	   were	   further	   incubated	   at	   37°C,	   5%	   CO2	   for	   approximately	   24	  
hours.	  At	   that	   time,	  compounds	  aliquoted	   in	  a	  384-­‐well	  plate	  were	  allowed	  to	  come	  to	  RT	  
for	  1	  hour	  and	  diluted	  to	  a	  final	  concentration	  of	  2.5	  μM	  by	  adding	  80	  μl/well	  of	  an	  EB	  cell	  
suspension	  made	  in	  RPMI	  without	  phenol	  red,	  supplemented	  with	  0.3	  mg/mL	  L-­‐glutamine,	  
5%	  (vol/vol)	  fetal	  bovine	  serum	  (FBS)	  and	  10	  μg/mL	  gentamycin.	  Cell	  culture	  medium	  was	  
aspirated	  from	  L929	  cells,	  seeded	  24	  hours	  previously	  by	  column,	  and	  54	  μl	  of	   treated	  EB	  
cell	   culture	   medium	   was	   transferred	   from	   the	   compound	   plate	   to	   the	   cells	   in	   the	  
corresponding	  wells.	  Once	  all	  cells	  were	  infected/treated,	  they	  were	  incubated	  for	  72	  hours	  
at	  37°C,	  5%	  CO2.	  Following	  this	  incubation,	  alamarBlue	  (Invitrogen)	  was	  added	  to	  each	  well	  
at	  a	  final	  concentration	  of	  10%	  (6	  μl/well)	  and	  allowed	  to	  incubate	  with	  the	  cells	  for	  8	  hours	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at	   37°C,	   5%	   CO2.	   Each	   plate	  was	   then	  wrapped	   in	   foil	   and	   stored	   at	   4°C.	   Once	   the	   initial	  
screen	  was	  completed,	  all	  plates	  were	  allowed	  to	  come	  up	  to	  RT	  and	  absorbance	  at	  570	  nm	  
and	   600	   nm	   was	   measured	   using	   a	   PowerWave	   microplate	   spectrophotometer	   (BioTek	  
Instruments,	   Inc.,	   Winooski,	   VT).	   Reducing	   capability	   was	   calculated,	   as	   described	  
previously	   (64)	  using	   the	   following	   formula;	  
(!!"  )!!  !!!!  (!!"  )!!  !!!
(!!"  )!!  !!!!!  (!!"  )!!  !!!!
	  ×	  100,	  where	   εOX	   is	   the	  
molar	  extinction	  coefficient	  of	  alamarBlue’s	  oxidized	  (blue)	  form,	  A	  is	  the	  absorbance	  of	  the	  
test	  wells,	  A’	  is	  the	  absorbance	  of	  the	  positive	  control	  wells	  (0.1%	  DMSO-­‐treated,	  uninfected	  
wells)	   and	   λ1	   and	   λ2	   are	   570	   nm	   and	   600	   nm,	   respectively.	   Hits	   were	   determined	   at	   2	  
standard	  deviations	  above	   the	  average	  of	   the	  samples.	  The	   initial	   small	  compound	   library	  
screened	   was	   the	   2007	   Prestwick	   Chemical	   Library	   obtained	   from	   the	   High-­‐throughput	  
Screening	   facility	   at	   the	   University	   of	   Kansas,	   which	   receives	   the	   compounds	   from	  
Prestwick	  Chemical	  in	  Illkirch,	  France.	  
	  
Dose-­‐dependent	  Confirmation:	  	  
Dose-­‐dependent	  confirmation	  screening	  was	  performed	  following	  the	  same	  protocol	  
as	   initial	   screening.	  A	   list	  of	  hits	   from	  the	   initial	   screen	  of	   the	  Prestwick	  Chemical	  Library	  
was	   sent	   to	   the	   High-­‐Throughput	   Screening	   Facility	   at	   The	   University	   of	   Kansas	   and	  
compounds	   were	   plated	   in	   different	   volumes	   to	   generate	   8	   final	   concentrations	   from	  
approximately	  20	  μM	  to	  0.156	  μM.	  Testing	   the	  compounds	  at	  a	  higher	  concentration	   than	  
2.5	  μM	  required	  additional	  volumes	  of	   the	  compound	  to	  be	  plated	  per	  well	  and	  therefore,	  
increased	  the	  final	  concentration	  of	  DMSO	  on	  the	  cells.	  Additional	  DMSO	  controls	  from	  0.8%	  
to	   0.1%	   were	   included	   to	   compare	   to	   the	   higher	   concentrations	   tested.	   Once	   the	   dose-­‐
dependent	  screen	  was	  completed,	  all	  plates	  were	  allowed	  to	  come	  up	  to	  RT	  and	  absorbance	  
at	  570	  nm	  and	  600	  nm	  was	  measured	  using	  a	  PowerWave	  microplate	  spectrophotometer	  
(BioTek	   Instruments,	   Inc.,	   Winooski,	   VT).	   Reducing	   capability	   was	   calculated	   as	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aforementioned	   using	   the	   corresponding	   percentage	   of	   DMSO-­‐treated,	   uninfected	   cells	   as	  
the	   positive	   control.	   Confirmation	   of	   the	   hits	  was	   determined	   at	   two	   standard	   deviations	  
above	   the	   average	   of	   the	   DMSO-­‐treated,	   infected	   controls	   with	   the	   corresponding	   final	  
concentration	  of	  DMSO	  per	  well.	  IC50	  was	  calculated	  using	  GraphPad	  Prism	  6.	  	  
	  
Inhibition	  of	  Commercially	  Purchased	  Compounds:	  
	  L929	   cells	   were	   seeded	   in	   a	   clear,	   flat	   bottom,	   96-­‐well,	   tissue	   culture	   plate	   at	  
1.0	  x	  105	  cells/mL;	  200	  μl/well	   and	   incubated,	   flat,	   at	   RT	   for	   1	   hour.	   Then,	   the	   cells	   were	  
allowed	  to	  further	  incubate	  for	  approximately	  24	  hours	  at	  37°C,	  5%	  CO2.	  The	  following	  day,	  
the	   cell	   culture	  medium	   (RPMI	   1640	  media	   (Cellgro	   by	  Mediatech;	  Manassas,	   VA	   20109)	  
with	   phenol	   red,	   supplemented	   with	   0.3	   mg/mL	   L-­‐glutamine,	   5%	   (vol/vol)	   fetal	   bovine	  
serum	   (FBS)	   and	   10	   μg/mL	   gentamycin)	   was	   aspirated	   off	   of	   the	   cells	   and	   EBs	   at	   a	  
concentration	   of	   6.0	   x	   10-­‐5	   in	   supplemented	   RPMI	   without	   phenol	   red	   and	   the	   desired	  
concentration	   of	   each,	   individual	   compound	   was	   added	   to	   the	   designated	   wells.	   This	  
mixture	  was	  allowed	  to	  incubate	  on	  the	  L929	  cells	  for	  72	  hours.	  Following	  this	  incubation	  a	  
final	  concentration	  of	  10%	  alamarBlue	  was	  added	  to	  each	  well	  and	  the	  plate	  continued	  to	  
incubate	   at	   37°C,	   5%	   CO2	   for	   an	   additional	   8	   hours.	   Finally,	   absorbance	   at	   570	   nm	   and	  
600	  nm	   was	   measured	   using	   a	   PowerWave	   microplate	   spectrophotometer	   (BioTek	  
Instruments,	   Inc.,	   Winooski,	   VT).	   Reducing	   capability	   was	   calculated,	   as	   described	  
previously.	  The	  following	  compounds	  were	  tested	  in	  this	  assay;	  antimycin	  A	  (Sigma	  Aldrich,	  
St.	   Louis,	   MO),	   artemisinin	   (Sigma	   Aldrich,	   St.	   Louis,	   MO),	   trazodone	   hydrochloride	  
(Sigma	  Aldrich,	   St.	  Louis,	  MO),	   mycophenolic	   acid	   (Santa	   Cruz	   Biotechnology),	   ofloxacin	  
(Sigma	   Aldrich,	   St.	  Louis,	  MO),	   roxithromycin	   (Sigma	   Aldrich,	   St.	   Louis,	   MO),	   tetracycline	  
hydrochloride	   (USB	  Corporation,	   Cleveland,	   OH)	   and	   ampicillin	   sodium	   salt	  
(Fisher	  Scientific,	  Fair	  Lawn,	  NJ).	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Toxicity	  Assay:	  	  
L929	   cells	   were	   seeded	   in	   a	   clear,	   flat	   bottom,	   96-­‐well,	   tissue	   culture	   plate	   at	  
1.0	  x	  105	  cells/mL;	  200	  μl/well	   and	   incubated,	   flat,	   at	  RT	   to	   reduce	   edge	   effect	   for	   1	   hour.	  
Following	  this	  time,	  the	  cells	  were	  allowed	  to	  further	  incubate	  for	  approximately	  24	  hours	  
at	  37°C,	  5%	  CO2.	  The	  following	  day,	  the	  cell	  culture	  medium	  (RPMI	  1640	  media	  (Cellgro	  by	  
Mediatech;	   Manassas,	   VA	   20109)	   with	   phenol	   red,	   supplemented	   with	   0.3	   mg/mL	   L-­‐
glutamine,	  5%	  (vol/vol)	  fetal	  bovine	  serum	  (FBS)	  and	  10	  μg/mL	  gentamycin)	  was	  aspirated	  
off	   and	   the	   desired	   concentration	   of	   each,	   individual	   compound	   was	   added	   to	   the	  
designated	   wells	   after	   being	   diluted	   in	   RPMI	   1640	   medium	   (Cellgro	   by	   Mediatech;	  
Manassas,	  VA	  20109)	  without	  phenol	  red,	  supplemented	  with	  0.3	  mg/mL	  L-­‐glutamine,	  5%	  
(vol/vol)	   fetal	   bovine	   serum	   (FBS)	   and	   10	   μg/mL	   gentamycin.	   The	   compounds	   were	  
allowed	  to	  incubate	  on	  the	  uninfected	  cells	  for	  either	  24	  or	  72	  hours	  at	  37°C,	  5%	  CO2	  prior	  
to	   addition	   of	   alamarBlue	   at	   a	   final	   concentration	   of	   10%.	   After	   an	   additional	   8	   hour	  
incubation	   at	   37°C,	   5%	   CO2,	   absorbance	   at	   570	   nm	   and	   600	   nm	   was	   measured	   using	   a	  
PowerWave	   microplate	   spectrophotometer	   (BioTek	   Instruments,	   Inc.,	   Winooski,	   VT).	  
Reducing	   capability	   was	   calculated,	   as	   described	   previously	   (64)	   using	   the	   following	  
formula;	  
(!!"  )!!  !!!!  (!!"  )!!  !!!
(!!"  )!!  !!!!!  (!!"  )!!  !!!!
	  ×	   100,	   where	   εOX	   is	   the	   molar	   extinction	   coefficient	   of	  
alamarBlue’s	  oxidized	  (blue)	  form,	  A	  is	  the	  absorbance	  of	  the	  test	  wells,	  A’	  is	  the	  absorbance	  
of	  the	  positive	  control	  wells	  (0.1%	  DMSO-­‐treated,	  uninfected	  wells)	  and	  λ1	  is	  570	  nm	  and	  λ2	  
is	   600	  nm.	   The	   following	   compounds	   were	   tested;	   antimycin	   A	   (Sigma	   Aldrich,	   St.	   Louis,	  
MO),	   artemisinin	   (Sigma	   Aldrich,	   St.	   Louis,	  MO),	   trazodone	   hydrochloride	   (Sigma	  Aldrich,	  
St.	  Louis,	  MO),	   mycophenolic	   acid	   (Santa	   Cruz	   Biotechnology),	   ofloxacin	   (Sigma	   Aldrich,	  
St.	  Louis,	  MO),	   roxithromycin	   (Sigma	   Aldrich,	   St.	   Louis,	   MO),	   tetracycline	   hydrochloride	  
(USB	  Corporation,	   Cleveland,	   OH)	   and	   ampicillin	   sodium	   salt	   (Fisher	   Scientific,	  
Fair	  Lawn,	  NJ).	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Immunofluorescence	  Assay:	  
L929	   cells	   were	   seeded	   in	   a	   glass	   bottom	   96-­‐well	   plate	   at	  
7.5	  x	  104	  cells/mL;	  200	  μl/well	  and	  incubated,	  flat,	  at	  RT	  to	  reduce	  edge	  effect.	  After	  1	  hour,	  
cells	   were	   incubated	   at	   37°C,	   5%	   CO2	   for	   approximately	   24	   hours.	   C.	  trachomatis	   EB	  
preparations,	  stored	  in	  SPG	  buffer	  at	  -­‐80°C,	  were	  brought	  to	  room	  temperature	  immediately	  
prior	   to	   infection	   and	   diluted	   to	   a	   final	   concentration	   of	   8	  x	  10-­‐5	   in	   Hank’s	   Balanced	   Salt	  
Solution,	   (HBSS;	   Mediatech,	   Inc.,	   Manassas,	   VA).	   The	   cell	   culture	   medium	   was	   aspirated	  
from	  the	  L929	  cell	  cultures	  and	  90	  μl/well	  of	  the	  diluted	  C.	  trachomatis	  cell	  suspension	  was	  
added.	  Following	  a	  two-­‐hour	   incubation,	   flat,	  at	  room	  temperature,	   the	   infection	  inoculum	  
was	   aspirated	   off	   and	   cell	   culture	  medium	   containing	   1	  μg/mL	   of	   cyclohexamide	   and	   the	  
desired	  concentration	  of	  each,	   individual	  compound	  was	  added	   to	   the	  designated	  wells	   in	  
triplicate.	  The	  cultures	  were	  then	   incubated	  at	  37°C,	  5%	  CO2.	  Cells	  were	   fixed	  at	  24	  hours	  
post	  infection	  (hpi)	  using	  100%	  methanol	  for	  10	  minutes	  at	  room	  temperature	  and	  washed	  
once	  with	  PBS.	  Cells	  were	  stained	  using	  the	  MicroTrack	  C.	  trachomatis	  culture	  confirmation	  
test	   (Syva	  Co.,	   Palo	  Alto,	  CA)	  diluted	  1:40	   in	  PBS	   (65	  μl/well)	   for	  110	  min	   in	   the	  dark.	   In	  
addition	  to	  the	  stain,	  1	  μg/mL	  4-­‐,6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  in	  PBS	  further	  diluted	  
1:100	  in	  PBS	  (7.5	  μl/well)	  was	  added	  to	  each	  well	  and	  allowed	  to	  incubate	  in	  the	  dark	  for	  an	  
additional	   15	  minutes.	   After	   staining,	   cells	  were	  washed	   three	   times	   for	   10	  minutes	  with	  
100	  μl/well	  of	  PBS.	  Prior	  to	  storage,	  approximately	  200	  μl/well	  of	  90%	  glycerol,	  0.1%	  Tris-­‐
HCl,	  pH	  8	  was	  added	  upon	  the	  removal	  of	  PBS.	  The	  plate	  was	  stored	  in	  the	  dark	  at	  4°C	  until	  
visualization.	   The	   following	   compounds	   were	   tested	   in	   this	   assay;	   antimycin	   A	   (Sigma	  
Aldrich,	  St.	  Louis,	  MO),	  artemisinin	  (Sigma	  Aldrich,	  St.	  Louis,	  MO),	  trazodone	  hydrochloride	  
(Sigma	  Aldrich,	   St.	  Louis,	  MO),	   mycophenolic	   acid	   (Santa	   Cruz	   Biotechnology),	   ofloxacin	  
(Sigma	   Aldrich,	   St.	  Louis,	  MO),	   roxithromycin	   (Sigma	   Aldrich,	   St.	   Louis,	   MO),	   tetracycline	  
hydrochloride	   (USB	  Corporation,	   Cleveland,	   OH)	   and	   ampicillin	   sodium	   salt	   (Fisher	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Scientific,	  Fair	  Lawn,	  NJ).	   Images	  were	  acquired	  and	   then	  analyzed	  using	  Cell	  Profiler	  and	  
Cell	  Profiler	  Analyst	  as	  previously	  described	  (63).	  	  
	  
Automated	  Screening:	  
	  	   L929	  cells	  were	   seeded	  at	  1.0	  x	  105	  cells/mL;	  50	  μl/well	   in	   a	   clear,	  384-­‐well	   tissue	  
culture	   plate	   (Thermo	   Scientific,	  Nunc	  164688)	   and	   incubated	   flat	   at	  RT	   for	   1	   hour.	   Cells	  
were	   further	   incubated	  at	  37°C,	  5%	  CO2	   for	  approximately	  24	  hours.	  Cell	   culture	  medium	  
was	   aspirated	   from	   L929	   cells,	   seeded	   24	   hours	   previously,	   and	   20	   μl	   of	   RPMI	   without	  
phenol	   red,	   supplemented	  with	   0.3	  mg/mL	   L-­‐glutamine,	   5%	   (vol/vol)	   fetal	   bovine	   serum	  
(FBS)	   and	   10	   μg/mL	   gentamycin	   was	   added	   per	   well.	   An	   EB	   cell	   suspension	   (5.6	  x	  10-­‐5)	  
generated	   in	   RPMI	   without	   phenol	   red,	   supplemented	   with	   0.3	  mg/mL	   L-­‐glutamine,	   5%	  
(vol/vol)	  fetal	  bovine	  serum	  (FBS)	  and	  10	  μg/mL	  gentamycin	  is	  added	  to	  each	  well	  and	  the	  
appropriate	   controls	   were	   added	   to	   the	   designated	   control	   wells.	   Following	   a	   72	   hour	  
incubation	   at	   37°C,	   5%	   CO2,	   alamarBlue	   (Invitrogen)	   was	   added	   to	   each	   well	   at	   a	   final	  
concentration	  of	  10%	  and	  allowed	  to	   incubate	  with	   the	  cells	   for	  8	  hours	  at	  37°C,	  5%	  CO2.	  
Absorbance	  at	  570	  nm	  and	  600	  nm	  was	  measured	  using	  a	  microplate	  spectrophotometer.	  




1. Adapting	  the	  Assay	  to	  384-­‐well	  Formation:	  
	  
a. Adjusting	  Cell	  Concentrations	  and	  EB	  Dilutions:	  
	  To	   adapt	   the	   assay	   to	   a	   384-­‐well	   format,	   several	   factors,	   including	   cell	  
concentration	   and	   EB	   dilution,	   needed	   to	   be	   adjusted.	   The	   first	   factor	   to	   be	   adjusted	   to	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adapt	   the	   resazurin-­‐based	   assay	   from	   96-­‐well	   format	   to	   384-­‐well	   format	  was	   the	   proper	  
concentration	  of	  L929	  cells	  per	  well.	  Two	  concentrations	  of	  host	  cells	  per	  well	  were	  tested	  
and	   the	   respective	   Z’	   factors	   were	   calculated	   using	   infected	   cells	   treated	   with	   a	   high	  
concentration	   of	   a	   known	   inhibitor	   of	   Chlamydia,	   1	  μg/mL	   tetracycline,	   as	   the	   positive	  
control	  and	   the	  DMSO	  treated/infected	  cells	  as	   the	  negative	  control.	  The	  wells	  with	  5,000	  
cells/well	   had	   a	   resulting	   Z’	   factor	   of	   0.52,	   indicating	   this	   is	   an	   excellent	   assay	   (Table	   1).	  
This	  was	  higher	  than	  the	  resulting	  Z’	  factor	  of	  0.35	  for	  15,000	  cells/well	  when	  infected	  with	  
the	  same	  concentration	  of	  purified	  EBs	  and	  thus,	  5,000	  cells/well	  was	  the	  cell	  concentration	  
used	  moving	  forward.	  	  
To	   develop	   an	   assay	   amendable	   for	   HTS	   a	   large	   dynamic	   range	   with	   low	   sample	  
variability	   is	   required.	   Therefore,	   an	   EB	   dilution	   that	   results	   in	   a	   high	   level	   of	   infection,	  
without	  over-­‐infecting	  the	  cells,	  and	  with	  low	  sample	  variability	  was	  desired.	  To	  identify	  a	  
dilution	   of	   EBs	   that	   satisfied	   those	   requirements,	   four	   different	   dilutions	   of	   purified	   EBs	  
were	   tested	   on	   5,000	   cells/well.	   The	   respective	   Z’	   scores	  were	   calculated,	   using	   1	  μg/mL	  
tetracycline,	   a	   concentration	   that	   should	   provide	   100%	   inhibition	   of	   infection,	   as	   the	  
positive	   control	   and	   DMSO-­‐treated	   infected	   cells	   as	   the	   negative	   control.	   The	   dilution	  
3.5	  x	  10-­‐5,	  which	  generates	  approximately	  a	  75%	  level	  of	  infection,	  resulted	  in	  the	  highest	  Z’	  
factor	  of	  0.74	  and	  was	  the	  EB	  dilution	  utilized	  in	  the	  following	  screens	  (Table	  1).	  	  
	  
b. Effect	  of	  DMSO	  on	  L929	  Cells:	  
The	  compounds	  to	  be	  screened	  for	  activity	  against	  Chlamydia	  are	  dissolved	  in	  100%	  
dimethyl	  sulfoxide	  (DMSO),	  an	  organic	  solvent	  that	  helps	  to	  prevent	  compound	  degradation	  
and	  to	  aid	  in	  enhancing	  the	  shelf	  life	  of	  the	  compound	  (71).	  Given	  that	  the	  resazurin-­‐based	  
assay	  tests	  cell	  viability,	  the	  final	  concentration	  of	  DMSO	  could	  not	  be	  cytotoxic	  to	  the	  host	  	  
	  
	  












	   	  




	   	  
Z’	  Factor	  
	   	  
Tested	  Value:	  
	   	  
Z’	  Factor:	  	  
	  
5,000	  
	   	  
0.52	  
	   3.5	  x	  10-­‐5	   	   0.74	  
	   4.5	  x	  10-­‐5	   	   0.65	  
	  
15,000	  
	   	  
0.35	  
	   5.5	  x	  10-­‐5	   	   0.63	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cells	  or	  the	  assay	  would	  not	  be	  functional.	  To	  test	  the	  cytotoxic	  effect	  of	  DMSO	  on	  uninfected	  
L929	   cells,	   three	   concentrations	   of	  DMSO	  diluted	   in	   cell	   culture	  medium	  were	   allowed	   to	  
incubate	  on	  L929	  cells	  for	  72	  hours	  prior	  to	  the	  addition	  of	  resazurin.	  It	  was	  found	  that	  5%	  
DMSO	  decreased	  the	  reducing	  capability,	  which	  corresponds	  to	  cell	  viability,	  of	  uninfected	  
L929	   cells	   by	   approximately	  85%,	   indicating	   that	   5%	  DMSO	  exposure	  over	  72	  hours	  was	  
cytotoxic	  (Fig.	  3).	  Cells	  exposed	  to	  1%	  DMSO	  demonstrated	  approximately	  a	  20%	  decrease	  
in	  reducing	  capability	  but	  cells	  exposed	  to	  0.2%	  DMSO	  had	  a	  slight	  to	  negligible	  decrease	  in	  
reducing	  capability	  compared	  to	   the	  control	  cells.	  The	   final	  concentration	  of	  DMSO	  on	  the	  
cells	   during	   the	   initial	   screen	   was	   approximately	   0.1%	   DMSO,	   which	   was	   deemed	   an	  
acceptable	  concentration	  during	  screening	  and	  had	  no	  obvious	  cytotoxic	  effects	  on	  the	  host	  
cells	  or	  the	  Chlamydia.	  
	  
c. Identification	  of	  Positive	  Controls:	  
Reference	   controls	   were	   also	   needed	   for	   the	   screen	   to	   finish	   adapting	   and	  
optimizing	   the	   screen	   to	   384-­‐well	   format.	   Since	   this	   is	   a	   colorimetric-­‐based	   assay,	   a	  mid-­‐
range	   inhibitor	   that	   exhibited	   approximately	  50%	   inhibition	  of	  Chlamydia	   infection	   and	   a	  
complete	   inhibitor	  of	   infection	  were	   ideal.	  Tetracycline	   is	   a	  known	   inhibitor	  of	  Chlamydia	  
and	   was	   therefore	   a	   likely	   candidate	   to	   utilize	   as	   a	   reference	   control.	   To	   identify	  
concentrations	   of	   tetracycline	   that	   fulfilled	   the	   desired	   reference	   controls,	   various	  
concentrations	   were	   tested.	   As	   previously	   reported,	   we	   observed	   concentrations	   higher	  
than	  0.5	  μg/mL	  resulted	  in	  complete	  inhibition	  of	  Chlamydia	  infection	  and	  dose	  dependent	  
inhibition	   for	   concentrations	   lower	   than	   0.5	   μg/mL	   (72).	   The	   two	   concentrations	   chosen	  
were	   0.25	   μg/mL	   and	   1	   μg/mL,	   which	   resulted	   in	   approximately	   50%	   inhibition	   and	  
complete	   inhibition	   of	   infection,	   respectively	   (Fig.	   4A).	   Additional	   controls	   for	   the	   screen	  
were	  chosen	  to	  ensure	  there	  were	  no	  measurable	  effects	  of	  DMSO	  on	  the	  eukaryotic	  host	  	  







Figure	   3:	   The	   Effect	   of	   DMSO	   on	   Uninfected,	   L929	   Cells.	   The	   effect	   of	   DMSO	   on	  
uninfected,	  L929	  cells	  was	  determined	  by	  incubating	  the	  tested	  concentrations	  of	  DMSO	  for	  
72	  hours	  on	  the	  cells	  prior	  to	  the	  addition	  of	  alamarBlue	  (resazurin).	  Eight	  hours	  later	  the	  
absorbance	   at	   570	  nm	   and	   600	  nm	   was	   measured	   using	   a	   spectrophotometer	   and	   the	  
reducing	  capability	  was	  calculated	  relative	   to	   the	  control	  containing	  0%	  DMSO.	  5%	  DMSO	  
was	  determined	  to	  be	  cytotoxic	  to	  the	  cells	  for	  this	  period	  of	  time	  and	  decreasing	  toxicity	  as	  
the	   concentration	   of	   DMSO	   decreased	   was	   observed.	   Error	   bars	   represent	   the	   standard	  
deviation	  of	  the	  samples.	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cells	   or	   the	   organism	   and	   represent	   the	   dynamic	   range	   of	   the	   assay	   by	   showing	   the	  
colorimetric	  scale	  from	  dark	  blue	  to	  fluorescent	  red	  (Fig.	  4B).	  	  
	  
2. Initial	  Screen	  of	  Prestwick	  Chemical	  Library:	  	  
To	   verify	   the	   utility	   and	   functionality	   of	   the	   assay	   the	   Prestwick	   Chemical	   library,	   a	  
small	   compound	   library	   containing	   many	   known	   antibiotics	   and	   agency	   approved,	   off-­‐
patent	  drugs,	  was	  screened	  for	  inhibitors	  of	  Chlamydia	  after	  adapting	  the	  assay	  to	  384-­‐well	  
format.	  In	  all,	  the	  Prestwick	  Chemical	  library	  is	  composed	  of	  1120	  compounds	  and	  contains	  
a	  variety	  of	  compounds	  with	  diverse	  medical	  purposes,	  mechanisms	  of	  action	  and,	  origins	  of	  
discovery.	   Following	   the	   initial,	   small-­‐scale	   screen	   52	   hits	   were	   identified	   at	   2	   standard	  
deviations	  above	  the	  sample	  average	  (Table	  2).	  Of	  those	  hits,	  41	  compounds	  were	  known	  to	  
have	   anti-­‐bacterial	   activity.	   The	   additional	   eleven	   compounds	   identified	   as	   hits	   were	   of	  
diverse	  medical	  uses	  and	  activities,	   including	  organ	  transplant	  rejection	  medications,	  anti-­‐
depressants,	  natural	  products,	  and	  anti-­‐malarial	  drugs.	  
Four	  separate	  384-­‐well	  plates	  were	  required	  for	  the	  library	  screen	  to	  test	  all	  1120	  of	  the	  
compounds.	   The	   resulting	   Z’	   factor	   for	   the	   plates	   were	   calculated	   individually	   using	   the	  
DMSO-­‐treated,	   uninfected	   and	   DMSO-­‐treated,	   infected	   cells	   as	   the	   positive	   and	   negative	  
controls,	   respectively	   and	   resulting	   factors	   were	   0.58,	   0.56,	   0.49,	   0.37.	   The	   resulting	   Z	  
factors	  for	  the	  plates	  individually	  were	  0.06,	  0.21,	  0.12	  and	  0.24.	  These	  Z	  factors	  were	  much	  
lower	  than	  anticipated	  based	  on	  the	  Z’	  factors	  calculated	  for	  the	  individual	  plates	  but	  due	  to	  
the	  high	  hit	  rate	  of	  over	  4.6%,	  and	  the	  identification	  of	  several	  highly	  inhibitory	  compounds,	  
the	  standard	  deviation	  of	  the	  sample	  averages	  was	  higher	  than	  expected,	  resulting	  in	  lower	  
Z	   factors.	  To	   illustrate	   this	  observation,	   the	  Z	   factors	  were	   re-­‐calculated	  using	   the	   sample	  
average	  and	  standard	  deviation	   in	  the	  absence	  of	   the	   identified	  hit	  values.	  The	  resulting	  Z	  
factors	  for	  the	  plates	  following	  those	  calculations	  were	  0.49,	  0.54,	  0.44	  and	  0.37,	  indicating	  	  







Figure	   4:	   Identification	   of	   Controls	   for	   Assay.	   Tetracycline	   is	   a	   known	   inhibitor	   of	  
Chlamydia,	  making	  it	  a	  good	  candidate	  for	  reference	  controls	  in	  this	  assay.	  Since	  this	  assay	  
is	  a	  colorimetric	  assay,	  a	  concentration	  of	  tetracycline	  that	  resulted	  in	  approximately	  50%	  
inhibition	   of	   Chlamydia	   and	   a	   concentration	   that	   resulted	   in	   complete	   inhibition	   were	  
desired.	  Of	  the	  tested	  concentrations,	  0.25	  μg/mL	  and	  1	  μg/mL	  fulfilled	  those	  requirements,	  
respectively,	  and	  were	  used	  as	  the	  reference	  controls	   for	  the	  resulting	  screens.	  Error	  bars	  
represent	  the	  standard	  deviation	  of	  the	  samples	  (A).	  In	  addition	  to	  the	  two	  concentrations	  
of	   tetracycline,	   there	   were	   four	   more	   controls	   used	   during	   screening,	   for	   a	   total	   of	   six	  
different	   controls;	   UU,	   uninfected/untreated	   cells,	   UT,	   infected/untreated	   cells,	   TL,	  
0.25	  μg/mL	   tetracycline,	   DUI,	   DMSO-­‐treated/uninfected	   cells,	   DI,	   DMSO-­‐treated/infected	  
cells,	  and	  TH,	  1	  μg/mL	  tetracycline	  (B).	  The	  cells	  that	  were	  not	  viable	  at	  the	  time	  alamarBlue	  
(resazurin)	  was	  added	  were	  not	  capable	  of	  converting	  the	  resazurin	  to	  resorufin	  and	  appear	  
dark	   blue.	   As	   the	   cell	   viability	   increases,	   the	   red	   color	   of	   the	   well	   increases	   due	   to	   an	  
increased	  amount	  of	  resorufin.	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Table	  2:	  Prestwick	  Chemical	  Library	  Initial	  Hits.	  	  
	  
Class:	  	  
	   	  
Compound:	  
	   Percent	  
Inhibition:	  
Anti-­‐bacterial:	   	   	   	  
Beta-­‐lactams:	   	   	  
Cyclacillin	  
Benzylpenicillin	  sodium	  
Metampicillin	  sodium	  salt	  







































































*Monensin	  sodium	  salt	  
*Clofazimine	  
*Nitrofural	  














Non-­‐antibacterial:	   	   	   	   	  

























Asterisks	  (*)	  indicate	  novel	  compounds	  without	  previously	  reported	  anti-­‐chlamydial	  activity.	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the	  effect	   the	  high	  hit	  rate	  and	  resulting	  data	  variation	  had	  on	  the	  calculated	  Z	   factors	   for	  
this	  library	  screen.	  	  
	  
3. Dose-­‐Dependent	  Confirmation	  of	  Hits:	  	  
To	   confirm	   the	   hits	   identified	   in	   the	   initial	   screen,	   eight	   concentrations	   of	   each	  
compound	  from	  20	  μM	  to	  0.156	  μM	  were	  screened	  for	  dose-­‐dependent	  analysis.	  Following	  
this	   subsequent	   screen,	   all	   of	   the	   compounds	  with	   known	   anti-­‐bacterial	   properties	   were	  
confirmed	  and	  accounted	  for	  approximately	  88%	  of	  the	  hits	  obtained	  (Table	  3).	  Of	  the	  four	  
classes	  of	   antibiotics	   that	   can	  be	  used	   to	   treat	  Chlamydia	   infections,	   the	  majority	  of	   these	  
compounds	   were	   beta-­‐lactam	   antibiotics,	   followed	   by	   tetracyclines,	   macrolides,	   and	  
fluoroquinolones.	   The	   remaining	   hits	   belonged	   to	   other	   families	   of	   antibiotics	   such	   as	  
chloramphenicol	  antibiotics	  and	  derivatives.	  The	  high	  percentage	  of	  hits	  with	  known	  anti-­‐
bacterial	   properties	   identified	   from	   screening	   the	   Prestwick	   Chemical	   library	   verified	   the	  
effectiveness	  of	   this	  method	  to	   identify	  compounds	  with	  activity	  against	  Chlamydia	  and	  of	  
the	   additional	   eleven	   compounds	   identified	   in	   the	   initial	   screen,	   six	   were	   confirmed	   by	  
dose-­‐dependent	   analyses.	   Since	   these	   compounds	   did	   not	   have	   previously	   reported	   anti-­‐
bacterial	   properties	   their	  mechanism	  of	   inhibition	   of	  Chlamydia	  was	   not	   known	   and	   they	  
were	   interesting	   and	   unexpected	   hits.	   The	   compounds	   with	   the	   top	   four	   percentages	   of	  
inhibition	  of	  Chlamydia	  were	  chosen	  for	  further	  investigation.	  	  
	  
4. Inhibition	  of	  Commercially	  Purchased	  Compounds:	  
To	  begin	  to	  delineate	  the	  mechanisms	  of	  inhibition	  exuded	  on	  Chlamydia	  by	  the	  top	  four	  
inhibitory,	   non-­‐antibacterial	   compounds	   identified	   in	   the	   initial	   screen	   of	   the	   Prestwick	  
Chemical	   Library,	   the	   following	   compounds,	   including	   positive	   controls	   were	   purchased	  
commercially;	  antimycin	  A,	  artemisinin,	  trazodone	  hydrochloride,	  mycophenolic	  acid,	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Table	  3:	  Prestwick	  Chemical	  Library	  Confirmed	  by	  Dose-­‐dependent	  Analysis.	  	  
	  
Class:	  
	   	  
Compound:	  
	   	  
IC50	  (μM):	  
Anti-­‐bacterial:	   	   	   	   	  






Metampicillin	  sodium	  salt	  




Nafcillin	  sodium	  salt	  
monohydrate	  
Amoxicillin	  




















































Other:	   	   	  



























Non-­‐antibacterial:	   	   	   	   	  













Asterisks	  (*)	  indicate	  novel	  compounds	  without	  previously	  reported	  anti-­‐chlamydial	  activity.	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ofloxacin,	   roxithromycin,	   ampicillin	   sodium	   salt,	   and	   tetracycline	   hydrochloride.	   The	   first	  
four	   compounds	   listed	   are	   compounds	   with	   miscellaneous	   drug	   purposes	   but	   were	  
identified	  and	  confirmed	  as	  hits	  in	  the	  screen	  of	  the	  Prestwick	  chemical	  library.	  Antimycin	  A	  
is	   a	   secondary	   metabolite	   produced	   by	   Streptomyces	   and	   is	   commercially	   used	   as	   a	   fish	  
poison.	  Artemisinin	  is	  an	  ancient,	  naturally	  derived	  drug	  used	  in	  combination	  to	  treat	  fever	  
and	  malaria.	  Trazodone	  hydrochloride	  is	  serotonin	  reuptake	  inhibitor	  medically	  used	  as	  an	  
anti-­‐depressant	   and	  mycophenolic	   acid	  was	   originally	   utilized	   as	   an	   immunosuppressant	  
drug	   to	   prevent	   organ	   transplant	   rejection.	   The	   final	   four	   compounds	   listed	   above	   were	  
used	  as	  positive	  controls	  in	  the	  assay	  because	  each	  one	  is	  a	  member	  of	  a	  different	  family	  of	  
antibiotics,	   all	   with	   varying	   mechanisms	   of	   action	   against	   Chlamydia.	   Ofloxacin	   is	   a	  
fluoroquinolone	   antibiotic	   and	   roxithromycin	   is	   a	  macrolide	   antibiotic,	  which	   is	   the	   same	  
family	  of	  antibiotics	  as	  azithromycin.	  Azithromycin	  is	  used	  to	  treat	  Chlamydia	  infections	  but	  
is	   not	   a	   compound	   included	   in	   the	   Prestwick	   Chemical	   Library	   and	   was	   therefore,	   not	  
obtained	  as	  a	  hit	  or	  used	  in	  further	  studies.	  Ampicillin	  is	  a	  beta-­‐lactam	  antibiotic,	  which	  is	  
the	  same	  family	  that	  includes	  amoxicillin,	  another	  anti-­‐biotic	  that	  can	  be	  used	  for	  treatment	  
of	   Chlamydia	   infection.	   Finally,	   tetracycline	   is	   a	   typical	   tetracycline	   with	   a	   similar	  
mechanism	  of	  action	  as	  doxycycline,	  the	  other	  commonly	  prescribed	  antibiotic	  used	  to	  treat	  
Chlamydia.	  	  
Once	   the	   compounds	   were	   received	   and	   solubilized	   they	   were	   tested	   in	   three	  
concentrations,	  5	  μM,	  2.5	  μM,	  and	  1.25	  μM.	  All	  of	  the	  compounds	  exuded	  measurable	  levels	  
of	  inhibition	  of	  Chlamydia	  as	  seen	  in	  the	  initial	  and	  dose-­‐dependent	  screens	  of	  the	  Prestwick	  
Chemical	   Library	   except	   trazodone	   hydrochloride,	   which	   did	   not	   exude	   any	   significant	  
inhibition	   (Fig.	   5).	   It	   is	   possible	   that	   the	   stock	   of	   trazodone	   hydrochloride	   that	   was	  
purchased	  commercially	  was	  inactive	  for	  an	  undetermined	  reason	  or	  there	  could	  have	  been	  
an	  error	  on	  the	  part	  of	  the	  HTS	  facility	  that	  plated	  the	  compounds	  for	  the	  initial	  and	  dose-­‐	  





Figure	  5:	   Inhibition	  of	  C.	  trachomatis	  with	  Commercially	  Purchased,	  Hit	  Compounds.	  
The	   four	   compounds	  without	  known	  anti-­‐bacterial	  properties	   that	   resulted	   in	   the	  highest	  
percent	  of	   inhibition	  of	  Chlamydia	  were	  purchased	  commercially	   for	   further	   investigation.	  
In	   addition	   to	   those	   four	   compounds,	   four	   positive	   controls,	   ampicillin,	   ofloxacin,	  
roxithromycin	   and	   tetracycline,	  were	   also	   included.	   To	   validate	   the	   screening	   results	   and	  
the	   activity	   of	   the	   compounds,	   dose-­‐dependent	   studies	   were	   performed.	   All	   of	   the	  
compounds	   resulted	   in	  measurable	   inhibition	   compared	   to	   the	   initial	   Prestwick	   Chemical	  
Library	   screen	   except	   trazodone	   hydrochloride,	   which	   did	   not	   result	   in	   measureable	  
inhibition	  of	  Chlamydia.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  samples.	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dependent	   screens	   of	   the	   Prestwick	   Chemical	   Library.	   Further	   analysis	   is	   required	   to	  
address	  this	  contrasting	  observation.	  	  
In	  addition	  to	  the	  absence	  of	  detectable	  inhibition	  by	  trazodone	  hydrochloride,	  the	  
resulting	   inhibition	   for	  mycophenolic	  acid	  was	  not	  dose-­‐dependent	  as	  would	  be	  expected.	  
Generally,	   when	   a	   compound	   is	   inhibitory,	   increasing	   the	   concentration	   will	   increase	  
inhibition	  until	  a	  saturation	  point	  is	  reached	  but	  increasing	  concentrations	  of	  mycophenolic	  
acid	   resulted	   in	   an	  observed	  decrease	  of	   inhibition.	  Given	   that	   resazurin	   is	   a	   cell	   viability	  
indicator,	  the	  health	  of	  the	  host	  cell	  will	   influence	  the	  results	  of	  the	  assay.	  In	  this	  case,	  the	  
reverse,	  dose-­‐dependent	  response	  may	   indicate	   that	  mycophenolic	  acid	   is	  cytotoxic	   to	   the	  
host	  cells	  for	  the	  72	  hour	  incubation	  period	  of	  the	  experiment.	  	  
	  
5. Toxicity	  of	  Compounds	  on	  L929	  Cells:	  	  
To	   test	   the	   cytotoxicity	   of	   the	   compounds	   on	   the	   L929	   cells,	   uninfected	   cells	   were	  
treated	   for	   either	   24	   hours	   or	   72	   hours	   with	   the	   compounds	   and	   their	   viability	   was	  
measured	  using	  resazurin.	  After	  a	  24	  hour	  incubation	  period,	  the	  reducing	  capability,	  which	  
corresponds	   with	   the	   cell	   viability,	   of	   the	   host	   cells	   treated	   with	   mycophenolic	   acid	  
decreased	  as	   the	  concentration	  of	   the	  compound	   increased	  (Fig.	  6A).	  This	   trend	  was	  even	  
more	  striking	  after	  a	  72	  hour	  incubation	  period	  with	  the	  reducing	  capability	  of	  the	  treated	  
host	   cells	   decreasing	   by	   over	   30%	  when	   treated	  with	   5	   μM	   and	   compared	   to	   the	  DMSO-­‐
treated,	   uninfected	   controls	   (Fig.	   6B).	   Interestingly,	   a	   decrease	   in	   the	   host	   cell	   reducing	  
capability	  for	  cells	  treated	  with	  antimycin	  A	  was	  also	  observed	  but	  was	  not	  as	  striking	  as	  the	  
resulting	  reducing	  capability	  for	  cells	  treated	  with	  mycophenolic	  acid	  (Fig.	  6).	  Following	  the	  
completion	  of	   these	  toxicity	  assays,	   it	  was	  apparent	  that	  mycophenolic	  acid	   is	  cytotoxic	   in	  
higher	   concentrations	   to	   uninfected	   L929	   cells	   for	   72	   hours	   and	   antimycin	   A	   also	   has	  
measureable,	  toxic	  effects	  on	  the	  uninfected,	  host	  cells.	  The	  observable	  cytotoxic	  effects	  by	  	  






Figure	   6:	   Toxicity	   of	   Compounds	   on	   Uninfected,	   L929	   Cells.	   For	   a	   compound	   to	   be	   a	  
suitable	  candidate	  to	  be	  used	  for	  treatment	  or	  a	  molecular	  probe,	  the	  compound	  must	  not	  
be	  cytotoxic	  to	  the	  host	  cells.	  To	  test	   the	  cytotoxicity	  of	   these	  compounds,	   the	  compounds	  
was	   diluted	   to	   the	   desired	   concentration	   in	   tissue	   culture	   medium	   and	   incubated	   on	  
uninfected,	  L929	  cells	  for	  24	  hours	  (A)	  and	  72	  hours	  (B).	  The	  two	  compounds	  that	  caused	  
the	  highest	  amount	  of	  host	  cell	  cytotoxicity	  were	  mycophenolic	  acid	  and	  antimycin	  A.	  The	  
observed	  cytotoxicity	  increased	  for	  both	  compounds	  as	  the	  incubation	  time	  increased.	  Error	  
bars	  indicate	  the	  standard	  deviation	  of	  the	  samples.	  	  
	   	  





	   	  
	   39	  
the	  compounds	  to	  the	  host	  cells	  could	  have	  resulted	  in	  the	  inversely	  related	  dose-­‐dependent	  
inhibition	  of	  Chlamydia	  by	  the	  resazurin-­‐based	  assay.	  
	  
6. Orthogonal	  Assay:	  	  
a. Immunofluorescence	  Assay:	  
To	   observe	   how	   antimycin	   A,	   artemisinin,	   mycophenolic	   acid	   and	   trazodone	  
hydrochloride	  may	  be	  inhibiting	  Chlamydia,	  L929	  cells	  were	  infected	  with	  purified	  EBs	  and	  
each	  compound	  was	  tested	  at	  three	  concentrations	  (5	  μM,	  2.5	  μM,	  1.25	  μM).	  At	  24	  hpi,	  cells	  
were	   fixed	   and	   stained	   and	   images	   were	   acquired.	   Inclusions	   were	   visible	   in	   all	   of	   the	  
samples	   except	   the	   DMSO-­‐treated,	   uninfected	   control	   wells,	   indicating	   that	   none	   of	   the	  
tested	   compounds	   at	   these	   concentrations	   were	   able	   to	   completely	   inhibit	   inclusion	  
formation	   (Fig.	   7).	   However,	   three	   of	   the	   four	   positive	   control	   compounds,	   ofloxacin,	  
roxithromycin,	   and	   tetracycline	   treatment	   resulted	   in	   a	   striking	   decrease	   of	   inclusion	  
formation	  and	  inclusion	  size,	  as	  expected	  (Fig.	  7H-­‐7J).	  	  
	  
b. Inhibition	  of	  Inclusion	  Formation:	  
To	  quantify	   the	  effect	  on	   inclusion	   formation	  by	  each	  compound,	   the	   images	  were	  
analyzed	  using	  Cell	  Profiler	  and	  Cell	  Profiler	  Analyst	  software,	  which	  utilizes	  an	  algorithm	  
that	   classifies	   infected	   cells	   and	   uninfected	   cells	   from	   each	   sample.	   Cells	   are	   classified	   as	  
infected	   by	   the	   presence	   of	   an	   inclusion	   in	   the	   cell.	   Although	   Cell	   Profiler/Cell	   Profiler	  
Analyst	  can	  measure	  inclusion	  size,	  it	  is	  not	  a	  factor	  that	  is	  included	  in	  determining	  whether	  
or	  not	  a	  host	  cell	  is	  infected.	  This	  is	  important	  to	  consider	  when	  examining	  the	  results	  from	  
this	   assay.	   It	   would	   appear	   antimycin	   A,	   artemisinin	   and	   mycophenolic	   acid	   do	   not	  
significantly	   inhibit	   Chlamydia	   (Fig.	   8),	   but	   upon	   closer	   examination	   of	   the	   images,	   it	   is	  
evident	  that	  the	  inclusions	  in	  the	  cells	  treated	  with	  these	  compounds	  are	  smaller	  than	  the	  	  






Figure	  7:	   Immunofluorescence	  Assay	   to	  Observe	   the	  Effect	  of	  Tested	  Compounds	  on	  
Chlamydia.	  L929	  cells	  were	  infected	  with	  C.	  trachomatis	  and	  treated	  with	  compounds	  at	  0	  
hpi.	   At	   24	   hpi,	   cells	   were	   fixed	   and	   stained	   to	   observe	   the	   individual	   effects	   of	   each	  
compound	   on	   Chlamydia.	   Images	   were	   captured	   at	   40x	   magnification.	   The	   0.1%	   DMSO-­‐
treated	  uninfected	  (DUI;	  A.)	  and	  infected	  (DI;	  B.)	  controls	  are	  represented	  in	  the	  top	  row	  of	  
images.	  Cells	  treated	  with	  the	  four	  non-­‐antibacterial	  compounds,	   trazodone	  hydrochloride	  
(Traz.;	  C.),	  mycophenolic	  acid	  (Myco.;	  D.),	  artemisinin	  (Art.;	  E.),	  and	  antimycin	  A	  (Ant.	  A;	  F.),	  
are	  also	  displayed	  in	  rows	  two	  and	  three.	  The	  final	  two	  rows	  of	   images	   include	  L929	  cells	  
treated	  with	  the	   four	  anti-­‐bacterial	  compounds,	  ampicillin	  (Amp.;G.),	  ofloxacin	  (Oflox.;	  H.),	  
roxithromycin	  (Rox.;	  I.)	  and	  tetracycline	  (Tet.;	  J.).	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Figure	   8:	   Inhibition	   of	   Inclusion	   Formation.	  Cells	  were	   infected	  with	  purified	  EBs	  and	  
compounds	  were	  added	  at	  0	  hpi.	  The	  cells	  were	  fixed	  and	  stained	  at	  24	  hpi	  and	  images	  were	  
captured.	  After	  acquiring	  images,	  Cell	  Profiler	  and	  Cell	  Profiler	  Analyst	  software	  was	  used	  to	  
determine	  the	  percent	   inhibition	  of	   inclusion	  formation	  relative	  to	  the	   infected	  control,	  DI	  
(DMSO-­‐treated,	   infected	   L929	   cells).	   Artemisinin	   and	   antimycin	   A	   were	   the	   only	   non-­‐
antibacterial	  compounds	  that	  resulted	  in	  measureable	  inhibition	  with	  artemisinin	  being	  the	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DMSO-­‐treated,	  infected	  control	  cells	  (Fig.	  7B,	  7D-­‐7F).	  Similar	  to	  the	  results	  of	  the	  resazurin-­‐
based	  microplate	  assay	  performed	  on	  these	  commercially	  purchased	  compounds,	  trazodone	  
hydrochloride	   did	   not	   exude	  measurable	   inhibition	   of	  Chlamydia	   inclusion	   formation	   and	  
the	  inclusions	  do	  not	  appear	  significantly	  smaller	  compared	  to	  the	  DMSO-­‐treated,	   infected	  
control	  inclusions.	  	  
	  
7. Automation	  of	  Screening	  Method:	  
	  
To	   confirm	   the	   assay	   is	  well	   suited	   for	   large	   scale	   screening	  of	   chemical	   libraries,	   the	  
HTS	   Facility	   at	   The	   University	   of	   Kansas,	   which	   is	   an	   independent,	   state-­‐of-­‐the-­‐art	   drug-­‐
discovery	  facility,	  automated	  the	  liquid	  handling	  steps	  of	  the	  assay,	  and	  verified	  the	  assay’s	  
reproducibility	   (73,	   74).	   The	   automated	   screening	   of	   this	   method	   confirmed	   a	   large	  
separation	   band	   of	   an	   approximate	   76-­‐fold	   difference	   between	   the	   DMSO-­‐treated,	  
uninfected	  cells	  and	  the	  DMSO-­‐treated,	  infected	  cells.	  The	  Z’	  factors	  using	  these	  two	  controls	  
were	   approximately	   0.86	   and	   0.80	   for	   two,	   separate,	   384-­‐well	   plates,	   indicating	   that	   the	  
assay	  is	  statistically	  acceptable	  for	  large-­‐scale	  screening	  of	  chemical	  libraries.	  In	  addition	  to	  
being	  found	  statistically	  acceptable,	  the	  assay	  was	  found	  to	  be	  highly	  reproducible	  and	  well	  




D. DISCUSSION	  	  
The	   aim	   of	   this	   study	   was	   to	   develop	   a	   high-­‐throughput	   screening	   method	   for	  
Chlamydia	  trachomatis	   by	   adapting	   a	   previously	   developed	   resazurin-­‐based	   microplate	  
assay	  to	  384-­‐well	  format,	  and	  automating	  the	  liquid	  handling	  steps,	  allowing	  for	  large	  scale	  
screening	  of	  compound	  libraries.	  One	  of	  the	  important	  advantages	  of	  using	  the	  cell	  viability	  
indicator,	   resazurin,	   in	   the	   high-­‐throughput	   screening	  method	   is	   the	   dual	   purpose	   of	   the	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indicator.	   In	   several	   high-­‐throughput	   screening	   methods,	   an	   additional,	   counter-­‐screen	  
must	  be	  performed	  on	  any	  hits	  identified	  to	  test	  eukaryotic	  cell	  cytotoxicity	  (75),	  but	  using	  
this	  method,	  the	  anti-­‐chlamydial	  compounds	  that	  may	  be	  identified	  during	  screening	  should	  
not	  be	  cytotoxic	  to	  the	  eukaryotic	  host	  cells.	  Even	  if	  a	  compound	  were	  a	  strong	  inhibitor	  of	  
Chlamydia,	   it	  would	  not	  be	   identified	   as	   a	  hit	   from	   the	   screen	  due	   to	   its	   cytotoxic	  nature,	  
making	  the	  host	  cells	  incapable	  of	  converting	  resazurin	  to	  resorufin.	  This	  dual	  function	  not	  
only	   makes	   the	   method	   more	   cost	   efficient	   by	   eliminating	   the	   need	   for	   an	   additional,	  
counter-­‐screen	  but	   it	   also	   reduces	   the	   time	   required	   to	   identify	   a	   strong,	   anti-­‐chlamydial,	  
lead	  compound.	  
The	   first	   steps	   in	   adapting	   the	   method	   from	   96-­‐well	   to	   384-­‐well	   format	   were	   to	  
identify	   the	   proper	   concentration	   of	   cells	   per	   well	   and	   to	   identify	   a	   dilution	   of	   EBs	   to	  
provide	  a	  consistent	  and	  sufficient	  level	  of	  infection	  in	  the	  chosen	  concentration	  of	  cells.	  It	  
was	  initially	  thought	  that	  a	  higher	  number	  of	  cells	  per	  well	  would	  provide	  more	  consistent	  
results	  by	  helping	  to	  reduce	  well-­‐to-­‐well	  variation.	  However,	  it	  was	  determined	  that	  5,000	  
cells	  per	  well	  was	  an	  optimum	  concentration	  capable	  of	  forming	  a	  confluent	  monolayer,	  and	  
growing	  over	  a	  72	  hour	  incubation	  period	  without	  severe	  cell	  death	  due	  to	  lack	  of	  sufficient	  
reagents.	  The	  chosen	  cell	  concentration	  also	  resulted	  in	  a	  Z’	  factor	  higher	  than	  0.5,	  which	  is	  
indicative	   of	   an	   excellent	   high-­‐throughput	   screening	   assay	   as	   originally	   described	   by	  
Zhang	  et	  al.	  (69).	  
After	   determining	   an	   appropriate	   concentration	   of	   cells,	   the	   next	   task	   was	   to	  
identify	  an	  appropriate	  dilution	  of	  EBs	  and	  it	  was	  critical	  to	  prevent	  over-­‐infecting	  the	  host	  
cells.	   If	   the	   host	   cells	   were	   over	   infected,	   cell	   lysis	   could	   occur	   earlier	   during	   the	  
developmental	  cycle,	  adding	  another	  variable	  into	  the	  assay,	  and	  potentially	  decreasing	  the	  
likelihood	  of	  identifying	  true	  hits.	  If	  more	  than	  one	  EB	  enters	  a	  cell,	  the	  separate	  inclusions	  
will	  eventually	  fuse	  into	  a	  larger,	  single	  inclusion	  and	  following	  the	  cell	  division	  of	  RBs	  and	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the	  asynchronous	  conversion	  of	  EBs,	  the	  inclusion	  will	  grow	  faster	  due	  to	  a	  higher	  number	  
of	   organisms.	   The	   larger	   inclusion	   will	   lead	   to	   earlier	   and	   less	   uniform	   host	   cell	   lysis,	  
increasing	  the	  variability	  of	  the	  end	  point	  of	  the	  assay.	  The	  chosen	  dilution	  with	  the	  highest	  
Z’	   score	   generated	   approximately	   a	   75%	   level	   of	   infection,	   which	   provided	   a	   large	  
separation	   band	   and	   was	   highly	   reproducible	   with	   low	   standard	   deviations	   between	  
samples.	  
	  It	  was	  critical	  to	  identify	  concentrations	  that	  gave	  consistent	  readings	  from	  well	  to	  
well	  to	  reduce	  the	  standard	  deviations	  of	  the	  samples.	  Z	  factor	  is	  significantly	  influenced	  by	  
the	   variation	   and	   dynamic	   range	   and	   is	   calculated	   using	   the	   following	   formula;	  
!   =   1  – (!!!!  !!!  )
|!!!  !!|
,	  where	  !!	  and	  !!	  are	  the	  standard	  deviation	  and	  mean,	  respectively,	  of	  the	  
sample	  data	  and  !!  	  and	  !! 	  indicate	  the	  standard	  deviation	  and	  the	  mean	  of	  the	  control	  data,	  
respectively.	  The	  standard	  deviations	  highly	  influence	  the	  Z’	  and	  Z	  factors	  for	  an	  assay	  or	  a	  
screen	   because	   the	   data	   variations	   of	   the	   sample	   and	   the	   respective	   control	   data	   are	  
multiplied	  by	  three	  and	  added	  to	  one	  another	  during	  the	  calculation	  of	  Z	  factor.	  If	  a	  screen	  
has	  high	  variability	  the	  resulting	  Z	  factor	  will	  be	  a	  lower	  than	  desired	  value,	  because	  even	  in	  
the	  presence	  of	  a	  wide	  separation	  band,	  the	  dynamic	  range	  is	  not	  capable	  of	  compensating	  
for	  the	  variability	  of	  the	  assay.	  High	  variability	  in	  the	  assay	  may	  also	  decrease	  the	  accuracy	  
of	  the	  assay,	  causing	  an	  increase	  in	  observed	  false	  positives.	  
The	   final	   step	   to	   complete	   the	   adaptation	   of	   the	   micro-­‐plate	   assay	   to	   384-­‐well	  
format	   and	   to	   prepare	   for	   the	   initial	   small-­‐scale	   screen	  was	   to	   identify	   positive	   controls.	  
Tetracycline	  was	  chosen	  as	  the	  positive	  control	  compound	  because	  it	  has	  been	  extensively	  
used	  as	  a	  chlamydial	  inhibitor	  and	  it’s	  mechanism	  of	  action	  is	  well	  studied.	  The	  goal	  was	  to	  
identify	   two	  concentrations	  of	   tetracycline	   that	  provided	  approximately	  50%	  inhibition	  of	  
Chlamydia	   and	   a	   concentration	   that	   fully	   inhibited	   the	   organisms’	   growth.	   The	   lower	  
concentration	  was	   intended	   to	   serve	   as	   a	   reference,	   colorimetric	   control	   allowing	   for	   the	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visual	   identification	   of	  mid-­‐level	   inhibitors,	   given	   that	   not	   all	   of	   the	   expected	   hits	   would	  
exude	  complete	  inhibition	  of	  Chlamydia.	  Throughout	  the	  initial,	  small	  screen	  and	  during	  the	  
identification	   of	   the	   lower	   concentration	   control,	   the	   amount	   of	   inhibition	   obtained	   by	  
0.25	  μg/mL	   tetracycline	  was	  not	   consistent.	  This	   observed	  variability	   could	  be	  due	   to	   the	  
potency	   of	   tetracycline	   as	   a	   Chlamydia	   inhibitor,	   which	   follows	   a	   steep	   dose-­‐dependent	  
response	  curve.	  Osaka	  et	  al.	  reported	  a	  60%	  increase	  in	  observable	  inhibition	  between	  0.1	  
and	   0.5	   μg/mL	   tetracycline,	   indicating	   that	   a	   small	   increase	   in	   the	   concentration	   of	   this	  
inhibitor	   can	   result	   in	   a	   significant	   decrease	   in	   Chlamydia	   infection.	   The	   small	   error	  
obtained	   during	   diluting	   tetracycline	   by	   manual	   pipetting	   could	   skew	   the	   actual	   final	  
concentration	  of	  the	  compound	  and	  therefore,	  effect	  the	  amount	  inhibition	  recorded.	  Even	  
given	   its	   inconsistency,	   it	   was	   still	   included	   as	   a	   control	   in	   the	   screen	   for	   visualization	  
purposes	  but	  was	  not	   included	  in	  any	  final	  calculations	  of	  Z’	  or	  Z	  factor	  scores	  to	  evaluate	  
the	  quality	  of	  the	  assay	  or	  the	  screen.	  	  
The	  Prestwick	  Chemical	  Library	  was	  screened	  following	  the	  adaptation	  to	  384-­‐well	  
format	  to	  verify	  the	  utility	  and	  functionality	  of	  the	  assay.	  The	  library	  is	  composed	  of	  1120	  
compounds	   in	   total	   and	   156	   of	   those	   compounds	   have	   diverse,	   anti-­‐bacterial	   activities.	  
Following	  the	   initial	  screen,	  41	  compounds	   identified	  had	  known	  anti-­‐bacterial	  properties	  
and	  belonged	   to	  a	  variety	  of	  anti-­‐bacterial	   classes.	  The	   identification	  of	  a	   large	  number	  of	  
hits	   with	   known	   anti-­‐bacterial	   properties,	   many	   of	   which	   belong	   to	   the	   four	   classes	   of	  
antibiotics	   known	   to	   be	   effective	   against	   Chlamydia,	   strongly	   suggests	   that	   the	   assay	   is	  
functional	   and	   capable	   of	   identifying	   anti-­‐chlamydial	   compounds	   from	   small,	   compound	  
libraries.	  The	  remaining	  compounds	  not	   identified	   in	  the	   library	  as	  hits	  but	  having	  known	  
anti-­‐bacterial	   properties	   could	   have	   remained	   unidentified	   for	   several	   reasons.	   The	  
compound,	   despite	   its	   drug	   uses,	  may	   have	   been	   cytotoxic	   to	   the	   L929	   host	   cells	   for	   the	  
assay’s	   required	   incubation	  period	  or	   the	   tested	   concentration	  may	  have	  been	   too	   low	   to	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exude	  the	  level	  of	  inhibition	  of	  Chlamydia	  to	  be	  identified	  as	  a	  hit.	  There	  are	  also	  a	  variety	  of	  
anti-­‐bacterials	  that	  are	  incapable	  of	  crossing	  the	  eukaryotic	  cell	  membrane,	  preventing	  their	  
mechanism	   of	   action	   from	   being	   effective	   against	   Chlamydia	   since	   it	   is	   an	   obligate,	  
intracellular	   organism	   that	   inhabits	   a	   parasitophorous	   vacuole.	   Of	   the	   anti-­‐bacterial	  
compounds	  that	  were	  identified	  in	  the	  initial	  screen,	  all	  41	  were	  confirmed	  during	  the	  dose-­‐
dependent	   confirmation,	   as	   expected,	   further	   validating	   that	   the	   hits	   obtained	   were	  
compounds	   with	   anti-­‐chlamydial	   activity	   and	   were	   not	   false	   positives.	   This	   confirmation	  
additionally	   verified	   the	   functionality	   of	   the	   assay	   and	   its	   potential	   utility	   as	   a	   true,	   HTS	  
method	  suitable	  for	  large	  scale	  screening	  of	  compounds.	  	  
In	   addition	   to	   the	   expected,	   large	   number	   of	   anti-­‐bacterial	   hits	   in	   the	   initial	   and	  
dose-­‐dependent	   screens,	   six	   compounds	   were	   identified	   that	   did	   not	   have	   previously	  
reported	  anti-­‐bacterial	  properties.	  Three	  of	  the	  four	  compounds	  with	  the	  highest	  percent	  of	  
inhibition	   of	   Chlamydia,	   antimycin	   A,	   artemisinin	   and	   mycophenolic	   acid,	   still	   exuded	  
measurable	  inhibition,	  as	  reported	  by	  the	  resazurin-­‐based	  assay,	  after	  being	  obtained	  from	  
a	   commercial	   sources	   for	   further	   investigation	   (Fig.	   5).	   Upon	   examination	   of	   the	   images	  
captured	   during	   IFA,	   none	   of	   these	   three	   compounds	   were	   capable	   of	   preventing	   the	  
formation	   of	   chlamydial	   inclusions,	   indicating	   that	   they	   may	   not	   have	   an	   effect	   on	  
Chlamydia’s	   entry	   into	   the	   eukaryotic	   host	   cell	   (Fig.	   7,	   Fig.	   8).	   However,	   each	   of	   the	  
compounds	   resulted	   in	   decreased	   inclusion	   size	   when	   compared	   to	   the	   DMSO-­‐treated,	  
infected	  control	  inclusions	  (Fig.	  7).	  	  
The	  resulting	  smaller	  inclusions	  and	  differences	  in	  measured	  inhibition	  between	  the	  
resazurin-­‐based	  assay	  and	   the	  observations	   from	   the	   immunofluorescence	  assay	   could	  be	  
caused	   by	   an	   effect	   of	   the	   compounds	   on	   Chlamydia’s	   developmental	   cycle.	   If	   the	  
developmental	  cycle	  is	  delayed,	  the	  host	  cells	  may	  not	  lyse	  by	  72	  hours	  post	  infection,	  when	  
the	  cell	  viability	  indicator	  is	  added	  for	  the	  resazurin-­‐based	  assay,	  and	  therefore,	  they	  would	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still	   be	   capable	   of	   converting	   resazurin,	   the	   form	   that	   is	   reduced	   by	   products	   of	   cell	  
metabolism,	  to	  resorufin.	  One	  of	  the	  positive	  controls,	  ampicillin,	   is	  an	  example	  of	  such	  an	  
event.	  This	  compound	  allows	  for	  the	  formation	  of	   inclusions,	  which	  are	  recognized	  by	  Cell	  
Profiler/Cell	   Profiler	   Analyst;	   however,	   the	   inclusions	   are	   not	   phenotypically	   normal	  
inclusions	  (Fig.	  7G).	  Beta-­‐lactam	  antibiotics	  stall	  the	  developmental	  cycle	  by	  disrupting	  the	  
division	  of	  RBs,	  generating	  enlarged	  RBs	  and	  what	  is	  termed	  aberrant	  inclusions	  (76).	  These	  
cells	  do	  not	   lyse	  by	  72	  hpi	  and	  are	   therefore,	  capable	  of	  converting	  the	  viability	   indicator.	  
This	  disruption	   in	   the	  developmental	   cycle	   is	   read	  by	   the	   resazurin-­‐based	  assay	  as	  viable	  
cells	  and	   is	   indicative	  of	   inhibition	  of	  Chlamydia	   in	  that	  assay,	  even	  though	  the	  removal	  of	  
the	   antibiotic	   allows	   Chlamydia	   to	   come	   out	   of	   its	   persistent	   state	   and	   resume	   normal	  
development	  (Fig	  5).	  	  
There	  are	  several	  essential	  growth	  stages	  throughout	  the	  chlamydial	  developmental	  
cycle	  that	  the	  compounds	  could	  be	  effecting	  if	  their	  mechanism	  of	  action	  is	  not	  lethal	  to	  the	  
bacterial	  organism.	  Two	  of	  the	  tested	  compounds,	  mycophenolic	  acid	  and	  antimycin	  A	  both	  
have	  measurable	   cytotoxic	   effects	   on	   the	   eukaryotic	   host	   cells,	   which	   could	   be	   indirectly	  
causing	   the	   observed	   effect	   on	   Chlamydia.	   Mycophenolic	   acid	   is	   known	   to	   act	   on	   inosine	  
monophosphate	   dehydrogenase,	  which	   controls	   the	   rate	   of	   GMP	   formation	   in	   the	   path	   of	  
purine	  synthesis	  and	  was	  used	  and	  recommended	  as	  an	   immunosuppressant	  drug	   for	   the	  
treatment	   of	   autoimmune	   diseases	   and	   to	   prevent	   organ	   transplant	   rejection	   (77).	  
Antimycin	  A	   is	   known	   to	   inhibit	   the	   oxidation	   of	   ubiquinol,	   disrupting	   the	   formation	   of	   a	  
proton	   gradient	   and	   the	  ATP	  production	   by	   oxidative	   phosphorylation	   (78,	   79).	   It	   is	  well	  
known	   that	   Chlamydia	   has	   a	   reduced	   genome	   and	   as	   an	   obligate,	   intracellular	   organism	  
requires	   a	   variety	   of	   nutrients	   and	   growth	   factors	   from	   the	   its	   eukaryotic	   host,	   including	  
sphingomyelin,	  and	  cholesterol,	  which	  can	  be	  used	  for	  inclusion	  membrane	  expansion	  and	  
other	  species	  of	  Chlamydia,	   including	  C.	  psittaci,	  have	  mechanisms	  of	   taking	  ATP	   from	  the	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host	   in	   exchange	   for	  ADP	   (50,	  80).	   If	   these	   compounds	  are	  having	  negative	  effects	  on	   the	  
host	  and	  preventing	  the	  organism	  from	  obtaining	  the	  nutrients	  it	  requires	  for	  growth,	  those	  
negative	   effects	  may	   be	   responsible	   for	   the	   observable	   effects	   on	   the	   organism	   following	  
treatment	  with	  each	  of	  these	  compounds,	  individually.	  	  
Unlike,	   antimycin	   A	   and	   mycophenolic	   acid,	   artemisinin	   does	   not	   cause	   any	  
observable	  cytotoxic	  effects	  on	   the	  host	  cells.	  However,	   it	   still	   exudes	   the	  most	  noticeable	  
effects	  on	  inclusion	  size	  and	  inhibition	  of	  inclusion	  formation,	  indicating	  it	  has	  a	  mechanism	  
of	  action	  unrelated	  to	  host	  cell	  cytotoxicity.	  Artemisinin,	  also	  known	  as	  qinghaosu	  has	  been	  
used	  to	  treat	  fever	  and	  malaria	  for	  many	  centuries	  in	  China	  and	  is	  a	  natural	  product	  derived	  
from	   the	   herb	   Artemisia	   annua	   (81).	   Recently,	   it	   has	   been	   used	   around	   the	   world	   in	  
combination	  with	  other	  antimalarials	  to	  treat	  malarial	  infections	  but	  Plasmodium	  resistance	  
has	  been	  observed	  (82).	  It	  is	  thought	  to	  kill	  the	  parasite	  by	  means	  of	  free	  radicals	  produced	  
by	   the	   presence	   of	   its	   endo-­‐peroxide	   bridge,	   leading	   to	   modification	   of	   malarial	   target	  
proteins.	  It	  is	  also	  known	  that	  artmisinin	  is	  hydrophobic	  and	  it	  has	  been	  shown	  to	  partition	  
into	   biological	   membranes	   and	   to	   localize	   to	   specific	   parasite	   membranes,	   vacuole	  
membranes	  and	  mitochondria	  (83).	  It	  is	  possible	  that	  if	  the	  compound	  is	  capable	  of	  crossing	  
eukaryotic	  membranes	  to	  get	  to	  the	  inclusion	  membrane	  and	  have	  exposure	  to	  Chlamydia,	  it	  
could	   be	   using	   a	   similar	   free	   radical	   mechanism	   to	   eliminate	   the	   bacterial	   organisms.	  
Further	   studies	   are	   required	   to	   fully	   investigate	   all	   three	   of	   these	   compounds’	   specific	  
mechanism	  of	   action	  but	   given	   the	   absence	  of	  host	   cell	   cytotoxicity	   and	   the	  most	   striking	  
effects	  on	  Chlamydia,	  artemisinin	  may	  be	  the	  best	  candidate	  to	  probe	  into	  the	  biology	  of	  this	  
organism	   or	   to	   possibly	   serve	   as	   a	   model	   molecule	   for	   a	   novel	   therapy.	   Adding	   these	  
compounds	  to	  infected	  cells	  at	  different	  critical	  points	  during	  the	  developmental	  cycle	  may	  
shed	   some	   light	   on	   the	   growth	   stage	   effected	   by	   the	   addition	   of	   each	   compound	   and	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incubating	   purified	   EBs	   prior	   to	   infection	   could	   indicate	   whether	   or	   not	   any	   of	   these	  
compounds	  play	  a	  role	  in	  EB	  attachment	  prior	  to	  entry	  into	  the	  cell.	  	  
Following	   the	   results	   of	   the	   initial	   screen,	   dose-­‐dependent	   confirmation,	   and	   the	  
orthogonal	   assay	   to	   further	   confirm	  and	  validate	   the	   resulting	  hits,	   the	   screening	  method	  
was	   adapted	   for	   automated	   liquid	   handling	   in	   collaboration	   with	   the	   HTS	   facility	   at	   The	  
University	   of	   Kansas.	   The	   HTS	   facility	   also	   confirmed	   the	   assay	   reproducibility	   and	  
determined	   that	   this	   method	   was	   statistically	   acceptable	   for	   high-­‐throughput	   screening.	  
Since	   that	   confirmation,	   the	   CMLD	   (Chemical	   Methodologies	   and	   Library	   Development)	  
compound	   library	  containing	  approximately	  5,200	  novel	  compounds	  with	  predicted	  drug-­‐
like	  activity	  has	  been	  screened	  in	  a	   fully	  automated	  format	  using	  the	  HTS	  resazurin-­‐based	  
method.	   The	   CMLD	   Library	   is	   a	   library	   of	   compounds	   synthetically	   derived	   using	   new	  
principles	  of	  scaffold	  design.	  The	  drug	  design	  principles	  used	  during	  the	  generation	  of	   the	  
library	   increases	   the	  probability	   that	   these	   compounds	  will	  have	  pharmacological	   activity	  
and	  drug-­‐like	  characteristics.	  Preliminary	  data	   indicate	  an	   initial	  hit	  rate	  of	  approximately	  
1.75%	   and	   dose-­‐dependent	   analysis	   is	   to	   soon	   follow.	   This	   resazurin-­‐based	   high-­‐
throughput	   screening	   assay	   serves	   as	   the	   first	   automated,	   high-­‐throughput	   screening	  
method	  capable	  of	  identifying	  anti-­‐chlamydial	  compounds	  that	  could	  be	  used	  as	  molecular	  
probes,	  model	  molecules	  or	  novel	  C.	  trachomatis	  therapies.	  It	  will	  also	  lead	  the	  way	  for	  the	  
development	   of	   HTS	   methods	   in	   other	   species	   of	   Chlamydia,	   such	   as	   C.	   psittaci,	   and	  
additional	   obligate	   intracellular	   organisms	   with	   significant	   public	   health	   impacts	   and	   a	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